? ds

Set	Items	Description
S1	193106	HEAT (1W) SHOCK (1W) PROTEIN?
S2	483	S1 AND HEAT (1W) SHOCK (1W) PROTEIN (1W) COMPLEX
S3	2604130	S2 AND BACTERIA OR BACTERIAL
S4	109	S3 AND S2
S5	91	RD (unique items)

? t s5/3,ab/1-45
>>>No matching display code(s) found in file(s): 65, 135, 342, 345, 398, 459

5/3,AB/1 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

11343491 Genuine Article#: 641CK Number of References: 65
Title: Coxiella burnetii as a query microorganism (ABSTRACT AVAILABLE)
Author(s): Lukacova M (REPRINT) ; Melnicakova J; Diaz MQ; Barak I
Corporate Source: Slovak Acad Sci,Inst Mol Biol,Dubravska Cesta 21/SK-84551 Bratislava//Slovakia/ (REPRINT); Slovak Acad Sci,Inst Mol Biol,SK-84551 Bratislava//Slovakia/; Slovak Acad Sci,Inst Virol,SK-84245 Bratislava//Slovakia/
Journal: BIOLOGIA, 2002, V57, N6 (DEC), P713-720
ISSN: 0006-3088 Publication date: 20021200
Publisher: SLOVAK ACADEMIC PRESS LTD, PO BOX 57 NAM SLOBODY 6, 810 05 BRATISLAVA, SLOVAKIA
Language: English Document Type: REVIEW
Abstract: Coxiella burnetii, obligate intracellular parasite of eukaryotic cells and agent of Q fever uses some sophisticated ways to penetrate and propagate in the host cell. It resides and replicates in acid environment of the phagolysosome. C. burnetii displays pleomorphism during its growth inside the host cell. The result of this pleomorphism is high resistance to the harsh environmental conditions. Virulence factors, as %heat% %shock% %proteins%, %protein% - lipopolysaccharide %complex% of the outer membrane, or phase variation, defend this bacterium from effect of the host immune response. Study of high and low virulence strains of C. burnetii is important in connection with its persistence in the host in case of chronic Q fever. Induction of cytokines - effect of cellular immune response - provides some differences in comparison with other Gram-negative %bacteria%. In particular the effect of C. burnetii to the induction of tumor necrosis factor in the mouse macrophages is low. Genetic study of this microorganism is extremely difficult due to its obligate intracellular nature. Recently published genetic transformation of C. burnetii to the ampicillin resistance and expression of green fluorescent protein enables studying its virulence factors with methods of molecular biology.

5/3,AB/2 (Item 2 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

11051567 Genuine Article#: 600TL Number of References: 37
Title: CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes (ABSTRACT AVAILABLE)
Author(s): Becker T; Hartl FU; Wieland F (REPRINT)
Corporate Source: BZH,Neuenheimer Feld 328/D-69120 Heidelberg//Germany/ (REPRINT); BZH,D-69120 Heidelberg//Germany/; Max Planck Inst Biochem,Dept Biochem,D-82152 Martinsried//Germany/
Journal: JOURNAL OF CELL BIOLOGY, 2002, V158, N7 (SEP 30), P1277-1285
ISSN: 0021-9525 Publication date: 20020930
Publisher: ROCKEFELLER UNIV PRESS, 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
Language: English Document Type: ARTICLE
Abstract: Tumor and viral antigens elicit a potent immune response by %heat% %shock% %protein%-dependent uptake of antigenic peptide with subsequent presentation by MHC I. Receptors on antigen-presenting cells

that specifically bind and internalize a %heat% %shock% %protein% -peptide %complex% have not yet been identified. Here, we show that cells expressing CD40, a cell surface protein crucial for B cell function and autoimmunity, specifically bind and internalize human Hsp70 with bound peptide. Binding of Hsp70-peptide complex to the exoplasmic domain of CD40 is mediated by the NH2-terminal nucleotide-binding domain of Hsp70 in its ADP state. The Hsp70 cochaperone Hip, but not the %bacterial% Hsp70 homologue DnaK, competes formation of the Hsp70-CD40 complex. Binding of Hsp70-ADP to CD40 is strongly increased in the presence of Hsp70 peptide substrate, and induces signaling via p38. We suggest that CD40 is a cochaperone-like receptor mediating the uptake of exogenous Hsp70-peptide complexes by macrophages and dendritic cells.

5/3,AB/3 (Item 3 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

05136853 Genuine Article#: VC545 Number of References: 31
Title: CHANGES IN B-LYMPHOCYTES AND T-LYMPHOCYTES ASSOCIATED WITH MYCOBACTERIA-INDUCED PROTECTION OF NOD MICE FROM DIABETES (Abstract Available)
Author(s): MARTINS TC; AGUAS AP
Corporate Source: UNIV OPORTO,SALAZAR INST BIOMED SCI,CTR EXPT CYTOL,RUA CAMPO ALEGRE 823/P-4150 OPORTO//PORTUGAL/; UNIV OPORTO,SALAZAR INST BIOMED SCI,DEPT ANAT/P-4150 OPORTO//PORTUGAL/
Journal: JOURNAL OF AUTOIMMUNITY, 1996, V9, N4 (AUG), P501-507
ISSN: 0896-8411
Language: ENGLISH Document Type: ARTICLE
Abstract: Most female NOD mice spontaneously develop insulin-dependent diabetes mellitus (IDDM) after the 4th month of age. We have recently reported that infection of 2-month-old NOD mice with Mycobacterium avium prevents IDDM expression in these mice. We have searched here for changes in splenic lymphocytes that are associated with the effect of M. avium vaccination. Three experimental groups of female NOD mice were studied: (i) animals infected with 10(8) viable M. avium %bacteria% (mice that become protected from IDDM); (ii) mice inoculated with 10(8) heat-killed (HK) M. avium bacilli, and (iii) untreated age-matched NOD mice. Similar treatments were given to mice of the NON strain which are related to NOD mice but do not develop IDDM. mow cytometry was used to compare M. avium-infected, HK M. avium inoculated and untreated NOD and NON mice with regard to subpopulations of splenic lymphocytes bearing the surface antigens CD3, CD4, CD8, IgM and B220. We found that M, avium infection of NOD mice caused a sustained enhancement in T cells that was due to an early and transient increase in CD8(+) T cells (detected at day 7 of infection). This was followed by marked augmentation in the number of CD4(+) T cells at days 14 and 30. There was also elevation in B220(+) B cells at days 14 and 30, and of IgM(+) B cells at day 30 of infection. Inoculation of NOD mice with HK mycobacteria, which did not prevent IDDM, failed to produce significant changes in the number of T and B cells. No significant enhancement in T and B cells was observed in NON mice that were injected with either viable or HK M. avium bacilli. In NOD mice that reached 16 months of age because of being protected from IDDM (due to the M, avium infection) there was an increase in B220(+) B cells. We conclude that: (i) M, avium-induced protection of NOD mice from diabetes depends on the viability of the %bacteria%; (ii) the protective effect of the infection is associated with an early and marked increase in helper T cells and with a smaller elevation in B cells; (iii) elevation in B cells, but not in T cells, is associated with long term mycobacteria-induced protection of NOD mice from IDDM. (C) 1996 Academic Press Limited

5/3,AB/4 (Item 4 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

be reversed by the addition of Mg2+ ATP. The reversible and Mg2+ ATP-dependent association of GroEL/ES with non-native proteins might explain its postulated role in both protein transport and oligomer assembly.

5/3,AB/8 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

13493331 PMID: 9178754
FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
Nichols M; Rientjes J M; Logie C; Stewart A F
European Molecular Biology Laboratory, Gene Expression Program, Heidelberg, Germany.
Molecular endocrinology (Baltimore, Md.) (UNITED STATES) Jun 1997, 11 (7) p950-61, ISSN 0888-8809 Journal Code: 8801431
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
The ligand-binding domains of steroid receptors convey ligand-dependent regulation to certain proteins to which they are fused. Here we characterize fusion proteins between a site-specific recombinase, FLP, and steroid receptor ligand-binding domains. These proteins convert ligand binding into DNA recombination. Thus, ligand binding is directly coupled to an enzyme activity that is easily measured by DNA rearrangements or heritable genetic changes in marker gene expression, as opposed to the multiple events leading to transcription. Recombination by a FLP-estrogen receptor (FLP-EBD) fusion is activated by all tested estrogens, whether agonists or antagonists, indicating that all induce EBD release from the 90-kDa %heat% %shock% %protein% %complex%. Altering the distance between FLP and the EBD domain in the fusion proteins, by reducing the included length of the estrogen receptor D domain, affects ligand efficacy. A FLP-EBD with no D domain shows reduced inducibility by agonists and, unexpectedly, complete insensitivity to induction by all antagonists tested. A FLP-EBD including some D domain shows a ligand-inducible phenotype intermediate to those displayed by FLP-EBDs containing all or none of the D domain. Thus, we observed a tethered interference between FLP and the EBD domains that differs depending on the distance between the two domains, the conformations induced by agonists or antagonists, and which presents a previously undetectable distinction between estrogen agonists and antagonists in yeast.

5/3,AB/9 (Item 1 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

07657236 References: 31
TITLE: CHANGES IN B AND T LYMPHOCYTES ASSOCIATED WITH MYCOBACTERIA-INDUCED PROTECTION OF NOD MICE FROM DIABETES
AUTHOR(S): MARTINS TC; AGUAS AP
CORPORATE SOURCE: UNIV OPORTO,SALAZAR INST BIOMED SCI,CTR EXPT CYTOL,RUA CAMPO ALEGRE 823/P-4150 OPORTO//PORTUGAL/ (Reprint); UNIV OPORTO,SALAZAR INST BIOMED SCI,DEPT ANAT/P-4150 OPORTO//PORTUGAL/
PUBLICATION: JOURNAL OF AUTOIMMUNITY, 1996, V9, N4 (AUG), P501-507
GENUINE ARTICLE#: VC545
ISSN: 0896-8411
LANGUAGE: ENGLISH DOCUMENT TYPE: ARTICLE

ABSTRACT: Most female NOD mice spontaneously develop insulin-dependent diabetes mellitus (IDDM) after the 4th month of age. We have recently reported that infection of 2-month-old NOD mice with Mycobacterium avium prevents IDDM expression in these mice. We have searched here for changes in splenic lymphocytes that are associated with the effect of M. avium vaccination. Three experimental groups of female NOD mice were studied: (i) animals infected with 10(8) viable M. avium %bacteria% (mice that become

protected from IDDM); (ii) mice inoculated with 10(8) heat-killed (HK) M. avium bacilli, and (iii) untreated age-matched NOD mice. Similar treatments were given to mice of the NON strain which are related to NOD mice but do not develop IDDM. mow cytometry was used to compare M. avium-infected, HK M. avium inoculated and untreated NOD and NON mice with regard to subpopulations of splenic lymphocytes bearing the surface antigens CD3, CD4, CD8, IgM and B220. We found that M, avium infection of NOD mice caused a sustained enhancement in T cells that was due to an early and transient increase in CD8(+) T cells (detected at day 7 of infection). This was followed by marked augmentation in the number of CD4(+) T cells at days 14 and 30. There was also elevation in B220(+) B cells at days 14 and 30, and of IgM(+) B cells at day 30 of infection. Inoculation of NOD mice with HK mycobacteria, which did not prevent IDDM, failed to produce significant changes in the number of T and B cells. No significant enhancement in T and B cells was observed in NON mice that were injected with either viable or HK M. avium bacilli. In NOD mice that reached 16 months of age because of being protected from IDDM (due to the M, avium infection) there was an increase in B220(+) B cells. We conclude that: (i) M, avium-induced protection of NOD mice from diabetes depends on the viability of the %bacteria%; (ii) the protective effect of the infection is associated with an early and marked increase in helper T cells and with a smaller elevation in B cells; (iii) elevation in B cells, but not in T cells, is associated with long term mycobacteria-induced protection of NOD mice from IDDM. (C) 1996 Academic Press Limited

5/3,AB/10 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

136231234 CA: 136(15)231234x PATENT
Vaccine against microbial pathogens
INVENTOR(AUTHOR): Colaco, Camilo Anthony Leo Selwyn
LOCATION: UK,
ASSIGNEE: Immunobiology Limited
PATENT: PCT International ; WO 200220045 A2 DATE: 20020314
APPLICATION: WO 2001GB3964 (20010904) *GB 200021757 (20000904)
PAGES: 27 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/02A; A61P-031/04B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

5/3,AB/11 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

135335116 CA: 135(23)335116f PATENT
Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
INVENTOR(AUTHOR): Srivastava, Pramod K.
LOCATION: USA
ASSIGNEE: Srivastava, Pramod
PATENT: U.S. Pat. Appl. Publ. ; US 20010034042 A1 DATE: 20011025
APPLICATION: US 759010 (20010112) *US 488393 (20000120)
PAGES: 39 pp., Cont.-in-part of U.S. Ser. Number 488393. CODEN: USXXCO
LANGUAGE: English CLASS: 435068100; C12P-021/06A; A61K-038/17B

5/3,AB/12 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

132193249 CA: 132(15)193249p PATENT
Therapeutic and prophylactic methods using heat shock proteins
INVENTOR(AUTHOR): Srivastava, Pramod K.
LOCATION: USA
ASSIGNEE: Fordham University
PATENT: United States ; US 6030618 A DATE: 20000229
APPLICATION: US 711918 (19960910) *US 527547 (19950913)
PAGES: 18 pp., Cont.-in-part of U.S. 5,935,576. CODEN: USXXAM
LANGUAGE: English CLASS: 424184100; A61K-038/00A; A61K-039/00B; A61K-035/12B

5/3,AB/13 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

131169282 CA: 131(13)169282c PATENT
Modified heat shock protein-antigenic peptide complex
INVENTOR(AUTHOR): Podack, Eckhard R.; Spielman, Julie; Yamazaki, Koichi
LOCATION: USA
ASSIGNEE: University of Miami
PATENT: PCT International ; WO 9942121 A1 DATE: 19990826
APPLICATION: WO 99US3561 (19990219) *US PV75358 (19980220)
PAGES: 139 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/00A; A61K-039/00B; A61K-039/002B; A61K-039/02B; A61K-039/12B; A61K-039/118B; A61K-039/385B; C07K-001/32B; A01N-037/18B DESIGNATED COUNTRIES: AL; AM; AT ; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE ; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

5/3,AB/14 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

131031041 CA: 131(3)31041s PATENT
Vaccine comprising noncovalent complexes between heat shock proteins and antigenic peptides, and its use in the treatment and prevention of cancer
INVENTOR(AUTHOR): Srivastava, Pramod K.
LOCATION: USA
ASSIGNEE: Fordham University
PATENT: PCT International ; WO 9929834 A1 DATE: 19990617
APPLICATION: WO 98US26401 (19981211) *US 988878 (19971211)
PAGES: 71 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-001/20A; C12N-015/11B; C12N-015/63B; C12N-015/85B; C12N-015/86B; C07H-021/02B; C07H-021/04B; A23J-001/00B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

5/3,AB/15 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126272363 CA: 126(21)272363a PATENT
Treatment or prevention of neoplastic and infectious diseases with immune response-augmenting heat shock/stress protein complexes, method for measuring tumor rejection, and heat shock protein 70-peptide complex purification
INVENTOR(AUTHOR): Srivastava, Pramod K.

LOCATION: USA
ASSIGNEE: Fordham University
PATENT: PCT International ; WO 9710001 A1 DATE: 19970320
APPLICATION: WO 96US14557 (19960911) *US 527391 (19950913)
PAGES: 85 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/385A; A61K-039/12B; A61K-039/02B; A61K-039/00B; A61K-035/12B; G01N-033/53B; G01N-033/555B; G01N-033/567B DESIGNATED COUNTRIES: AL; AM; AU; AZ; BA; BB; BG; BR; BY; CA; CN; CU; CZ; EE; FI; GE; HU; IL; IS; JP; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MD; MG; MK; MN; MX; NO; NZ; PL; RO; RU; SG; SI; SK; TJ; TM; TR; TT; UA; UZ; VN; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

5/3,AB/16 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

126233701 CA: 126(18)233701q PATENT
Therapeutic and prophylactic methods using heat shock protein-antigen complexes to elicit immune responses
INVENTOR(AUTHOR): Srivastava, Pramod K.
LOCATION: USA
ASSIGNEE: Fordham University
PATENT: PCT International ; WO 9710000 A1 DATE: 19970320
APPLICATION: WO 96US14556 (19960911) *US 527547 (19950913) *US 711918 (19960910)
PAGES: 57 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/385A; A61K-039/12B; A61K-039/02B; A61K-039/00B; A61K-035/12B
DESIGNATED COUNTRIES: AL; AM; AU; AZ; BA; BB; BG; BR; BY; CA; CN; CU; CZ; EE; FI; GE; HU; IL; IS; JP; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LV; MD; MG; MK; MN; MX; NO; NZ; PL; RO; RU; SG; SI; SK; TJ; TM; TR; TT; UA; UZ; VN; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG ; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

5/3,AB/17 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal

13475094 PASCAL Number: 98-0172149
INTERACTION ENTRE LES MACHINES CHAPERONS DNAK/DNAJ/GRPE ET GROEL/GROES ET LEURS PROTEINES SUBSTRATS
(INTERACTION BETWEEN DNAK/DNAJ/GRPE AND GROEL/GROES CHAPERONE MACHINES AND THEIR PROTEIN SUBSTRATES)
DE CROUY CHANEL Axelle; RICHARME Gilbert, dir
Universite de Paris 07, Paris, Francee
University: Universite de Paris 07. Paris. FRA Degree: Th. doct.
1997-07; 1997 199 p.
Language: French Summary Language: French; English
Les molecules chaperons forment une classe de proteine qui fixent selectivement les polypeptides naissants, non replies, mal replies, ou agreges, en reconnaissant des regions hydrophobes exposees par les proteines depliees. Cette propriete est la base de l'implication des machines chaperons (DnaK/DnaJ/GrpE) et (GroEL/GroES) dans des processus cellulaires tels que le repliement, l'adressage, la renaturation des proteines, et le controle des interactions proteine-proteine. Les chaperons fonctionnent en collaboration avec leur cochaperon. Nous avons etudie l'interaction entre les machines chaperons d'E. coli et leurs substrats proteiques et l'effet produit par la presence des cochaperons. GroES diminue la specificite de GroEL pour les acides amines hydrophobes et augmente celle pour les acides amines hydrophiles. DnaJ attenue les sites hydrophobes de DnaK cependant qu'il renforce le site Arg/Lys. Par ailleurs, DnaJ augmente significativement l'interaction entre DnaK et les peptides en helice alpha . Au contraire des Hsp90 qui semblent interagir avec de nombreuses proteines natives, DnaK et GroEL interagissent principalement avec des proteines depliees. Cependant, nous avons montre que DnaK et GroEL

interagissent plus frequemment qu'on ne le suppose avec les proteines natives. L'affinite de DnaK est en correlation avec l'hydrophobicite de surface des proteines natives. Nous avons etudie l'interaction entre DnaK et les proteines membranaires, et nous avons montre que DnaK interagit fortement avec les proteines membranaires solubilisees et beaucoup moins avec celles inserees dans les membranes. Enfin, dans une etude in vitro, nous avons montre que DnaJ presente une activite proteine disulfure isomerase. Et nous presentons en plus, un travail portant sur l'expression et l'etat d'oxydoreduction des proteines d'E.coli dans des mutants redox et notamment des mutants de dnaJ.

5/3,AB/18 (Item 2 from file: 144)
DIALOG(R)File 144:Pascal

09991051 PASCAL Number: 92-0211830
A molecular chaperone from a thermophilic archaebacterium is related to the eukaryotic protein t-complex polypeptide-1
TRENT J D; NIMMESGERN E; WALL J S; HARTL F U; HORWICH A L
Howard Hughes medical inst., Yale school medicine, dep. genetics, New Haven CT 06510, USA
Journal: Nature : (London), 1991, 354 (6353) 490-493
Language: English

5/3,AB/19 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005610534
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James, INV
Hartl, Franz-Ulrich, INV
Hoe, Mee, INV
Houghton, Alan, INV
Takechi, Yoshizumi, INV
Mayhew, Mark, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040071725	A1	20040415	US 2003367668	20030214
Division	US 6663868			US 9811645	19980213
Continuation	US 6656679			US 2001794517	20010227
A371	PENDING			WO 96US13363	19960816
Provisional				US 60-2490	19950818
Provisional				US 60-2479	19950818

Fulltext Word Count: 11331

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers

5/3,AB/20 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005610533
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James, INV
Hartl, Franz-Ulrich, INV
Hoe, Mee, INV
Houghton, Alan, INV
Takechi, Yoshizumi, INV
Mayhew, Mark, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040071724	A1	20040415	US 2003367658	20030214
Division	US 6663868			US 9811645	19980213
Continuation	US 6641812			US 2001794529	20010227
A371	PENDING			WO 96US13363	19960816
Provisional				US 60-2490	19950818
Provisional				US 60-2479	19950818

Fulltext Word Count: 11334

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers

5/3,AB/21 (Item 3 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005610532
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James, INV
Hartl, Franz-Ulrich, INV
Hoe, Mee, INV
Houghton, Alan, INV
Takechi, Yoshizumi, INV
Mayhew, Mark, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040071723	A1	20040415	US 2003367654	20030214
Continuation	PENDING			US 2000636295	20000810
Continuation	US 6663868			US 9811645	19980213
A371	PENDING			WO 96US13363	19960816
Provisional				US 60-2490	19950818
Provisional				US 60-2479	19950818

Fulltext Word Count: 11295

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers

5/3,AB/22 (Item 4 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005610531
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James, INV
Hartl, Franz-Ulrich, INV
Hoe, Mee, INV
Houghton, Alan, INV
Takechi, Yoshizumi, INV
Mayhew, Mark, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040071722	A1	20040415	US 2003367594	20030214
Division	US 6663868			US 9811645	19980213
Continuation	PENDING			US 2000680806	20001005
A371	PENDING			WO 96US13363	19960816
Provisional				US 60-2490	19950818
Provisional				US 60-2479	19950818

Fulltext Word Count: 11389

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers

5/3,AB/23 (Item 5 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005610530
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James, INV
Hartl, Franz-Ulrich, INV
Hoe, Mee, INV
Houghton, Alan, INV
Takechi, Yoshizumi, INV
Mayhew, Mark, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040071721	A1	20040415	US 2003367593	20030214
Continuation	US 6663868			US 9811645	19980213
A371	PENDING			WO 96US13363	19960816
Provisional				US 60-2490	19950818
Provisional				US 60-2479	19950818

Fulltext Word Count: 11333

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination

with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers

5/3,AB/24 (Item 6 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005610529
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James, INV
Hartl, Franz-Ulrich, INV
Hoe, Mee, INV
Houghton, Alan, INV
Takechi, Yoshizumi, INV
Mayhew, Mark, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040071720	A1	20040415	US 2003367580	20030214
Division	US 6663868			US 9811645	19980213
Continuation	US 6673348			US 2001794832	20010227
A371	PENDING			WO 96US13363	19960816
Provisional				US 60-2490	19950818
Provisional				US 60-2479	19950818

Fulltext Word Count: 9437

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers

5/3,AB/25 (Item 7 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005610465
Derwent Accession: 2003-646068
Modulation of heat-shock-protein-based immunotherapies
Inventor: Wieland, Felix, INV
Hartl, Franz-Ulrich, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040071656	A1	20040415	US 2002328953	20021223
Provisional				US 60-342570	20011226
Provisional				US 60-343884	20011227
Provisional				US 60-372620	20020412
Provisional				US 60-399342	20020729
Provisional				US 60-414834	20020928

Fulltext Word Count: 33999
Abstract:
Methods and compositions are provided for modulating the immune response to an antigen based upon the finding that the cell surface protein CD40 is a mammalian heat shock protein (hsp) receptor. Cell

surface CD40 mediates the binding, cell signaling, and uptake of hsp and particularly hsp with antigen bound thereto. Methods are provided for modulating hsp-antigen uptake and an immune response to the antigen by altering CD40 expression, as well as utilizing CD40-binding fragments of mammalian hsp and muteins thereof for targeting antigens to CD40-expressing cells. Screening methods for agonists and antagonists of the CD40-hsp interaction are also provided.

5/3,AB/26 (Item 8 from file: 654)
DIALOG(R)File 654:US Pat.Full.

5605610
Derwent Accession: 1997-165035
Utility
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James E., New York, NY
Hartl, Franz Ulrich, Kottgeisering, DE
Hoe, Mee H., Irvington, NY
Houghton, Alan, New York, NY
Takeuchi, Yoshizumi, Kobe, JP
Mayhew, Mark, New York, NY
Assignee: Sloan-Kettering Institute for Cancer Research (02), New York, NY
Examiner: Ungar, Susan (Art Unit: 162)
Assistant Examiner: Davis, Minh-Tam
Law Firm: Kenyon & Kenyon

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6719974	A	20040413	US 2000680806	20001005
Division	Pending			US 11645	

Fulltext Word Count: 11431

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a %heat% %shock% %protein% complexed to a hybrid antigen comprising an antigenic domain and a %heat% %shock% %protein% -binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.

5/3,AB/27 (Item 9 from file: 654)
DIALOG(R)File 654:US Pat.Full.

5580766
Derwent Accession: 1998-495549
Utility
Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
Inventor: Henot, Frederic, Brussels, BE
Legon, Thierry, Korbeek Lo, BE
Duchateau, Jean, Soignies, BE
Servais, Genevieve, Soignies, BE
Assignee: Biotech Tools S.A. (03), Brussels, BE
Examiner: Page, Thurman K. (Art Unit: 165)
Assistant Examiner: Di Nola-Baron, Liliana
Law Firm: Merchant & Gould, P.C.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6709672	A	20040323	US 2001891148	20010625

CIP	US 6312711	A	US 99380548	19991028
Priority			BE 97199	19970305

Fulltext Word Count: 11637

Abstract:
The present invention is related to a process for obtaining a composition comprising peptides bound to one or more %heat% %shock% %protein%(s) and for possibly recovering from said composition the bound peptides, wherein the peptides resulting from a previously in-vitro hydrolysis of at least one immunogenic and antigenic macromolecular structure, are mixed in-vitro with one or more %heat% %shock% %protein% (s).
The present invention is also related to the compositions obtained by said process

5/3,AB/28 (Item 10 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005560396
Derwent Accession: 2002-154969
Method of identifying conformation-sensitive binding peptides and uses thereof
Inventor: Fowlkes, Dana, INV
Barnett, Thomas, INV
Buehrer, Benjamin, INV
Correspondence Address: BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040043420	A1	20040304	US 2003332708	20030708
PCT				WO 2001US21867	20010711

Fulltext Word Count: 43737

Abstract:
Peptides which bind a cellular (surface or intracellular) receptor, such as a nuclear receptor, may be identified by screening a combinatorial peptide library presented in the form of cells each of which coexpress one member peptide and the receptor, together with a signal producing system for reporting binding. A "two-hybrid" assay is of particular interest. The screen may be carried out in the presence of a ligand, in particular, an exogenous ligand. If this screening is carried out for a plurality of different receptor conformations, then this library screening will also serve to identify conformation-specific peptides for the receptor, which may then be used in a panel for "fingerprinting" query compounds as to their ability to interact with the receptor in the presence of each of the panel peptides. These fingerprints may be compared to those of reference compounds with known biological activities mediated by that receptor.

5/3,AB/29 (Item 11 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005560395
Derwent Accession: 2002-017594
Javelinization of protein antigens to %heat% %shock% %proteins%
Inventor: Rothman, James, INV
Hoe, Mee, INV
Mayhew, Mark, INV

Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040043419	A1	20040304	US 2003258147	20030813
PCT				WO 2001US12567	20010417

Fulltext Word Count: 8645

Abstract:
The present invention relates to antigenic complexes, wherein an antigenic complex comprises a peptide or protein containing a plurality of epitopes non-covalently joined to a %heat% %shock% %protein% via a molecular tether referred to as a "javelin". Such complexes do not require that each epitope Be defined, and may in certain embodiments, elicit both antibody and cell-mediated immune reactions. The complexes of the invention may be used to induce therapeutic immune responses directed toward the treatment or prevention of infectious diseases and malignancies

5/3,AB/30 (Item 12 from file: 654)
DIALOG(R)File 654:US Pat.Full.

5489837
Derwent Accession: 1997-165035
Utility
C/ %Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James E., New York, NY
Hartl, F. Ulrich, Munich, DE
Hoe, Mee H., New York, NY
Houghton, Alan, New York, NY
Takeuchi, Yoshizumi, Kobe, JP
Mayhew, Mark, Tarrytown, NY
Assignee: Sloan-Kettering Institute for Cancer Research (02), New York, NY
Sloan-Kettering Institute for Cancer Research (Code: 01305)
Examiner: Housel, James (Art Unit: 168)
Assistant Examiner: Brown, Stacy S.
Law Firm: Kenyon & Kenyon

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6673348	A	20040106	US 2001794832	20010227
Division	Pending			US 11645	

Fulltext Word Count: 9579

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a %heat% %shock% %protein% complexed to a hybrid antigen comprising an antigenic domain and a %heat% %shock% %protein% -binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.

5/3,AB/31 (Item 13 from file: 654)
DIALOG(R)File 654:US Pat.Full.

5468530
Derwent Accession: 1997-165035
Utility

C/ %Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James E., New York, NY
Hartl, Franz Ulrich, Kottgeisering, DE
Hoe, Mee H., Irvington, NY
Houghton, Alan, New York, NY
Takeuchi, Yoshizumi, Kobe, JP
Mayhew, Mark, New York, NY
Assignee: Sloan-Kettering Institute for Cancer Research (02), New York, NY
Sloan-Kettering Institute for Cancer Research (Code: 01305)
Examiner: Ungar, Susan (Art Unit: 162)
Assistant Examiner: Davis, Minh Tam
Law Firm: Kenyon & Kenyon

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6663868	A	20031216	US 9811645	19980213
PCT	WO 9706821		19970227	WO 96US13363	19960816
		371:			
		102e:			

Fulltext Word Count: 10769

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a %heat% %shock% %protein% complexed to a hybrid antigen comprising an antigenic domain and a %heat% %shock% %protein% -binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.

5/3,AB/32 (Item 14 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005456989
Derwent Accession: 2004-060539
Method of identifying conformation-sensitive binding peptides and uses thereof
Inventor: Fowlkes, Dana, INV
Barnett, Thomas, INV
Buehrer, Benjamin, INV
Assignee: Karo Bio AB (02), Huddinge, SE
Correspondence Address: BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030224390	A1	20031204	US 2003346162	20030117
CIP	PENDING			WO 2001US21867	20010711
CIP	PENDING			US 2001860688	20010521
CIP	ABANDONED			US 2000614865	20000712

Fulltext Word Count: 45376

Abstract:
Peptides which bind a cellular (surface or intracellular) receptor, such as a nuclear receptor, may be identified by screening a combinatorial peptide library presented in the form of cells each of which coexpress one member peptide and the receptor, together with a signal producing system for reporting binding. A "two-hybrid" assay is of particular interest. The screen may be carried out in the presence of a ligand, in particular, an exogenous ligand. If this screening is carried out for a plurality of different receptor conformations, then this library screening will also serve to identify conformation-specific

peptides for the receptor, which may then be used in a panel for "fingerprinting" query compounds as to their ability to interact with the receptor in the presence of each of the panel peptides. These fingerprints may be compared to those of reference compounds with known biological activities mediated by that receptor.

5/3,AB/33 (Item 15 from file: 654)
DIALOG(R)File 654:US Pat.Full.

5451850
Derwent Accession: 1997-165035
Utility
C/ %Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James E., New York, NY
Hartl, F. Ulrich, Munich, DE
Hoe, Mee H., New York, NY
Houghton, Alan, New York, NY
Takeuchi, Yoshizumi, Kobe, JP
Mayhew, Mark, Tarrytown, NY
Assignee: Sloan-Kettering Institute for Cancer Research (02), New York, NY
Sloan-Kettering Institute for Cancer Research (Code: 01305)
Examiner: Housel, James (Art Unit: 168)
Assistant Examiner: Brown, Stacy S.
Law Firm: Kenyon & Kenyon

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6656679	A	20031202	US 2001794517	20010227
Division	Pending			US 11645	

Fulltext Word Count: 9715

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heart shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.

5/3,AB/34 (Item 16 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005440800
Derwent Accession: 2003-679635
Modulation of immune response by non-peptide binding stress response polypeptides
Inventor: Nicchitta, Christopher, INV
Baker-LePain, Julie, INV
Assignee: Duke University (02)
Correspondence Address: JENKINS & WILSON, PA, 3100 TOWER BLVD SUITE 1400, DURHAM, NC, 27707, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030216315	A1	20031120	US 2003367093	20030213
Provisional				US 60-356293	20020213

Fulltext Word Count: 33405

Abstract:
A recombinant stress response polypeptide that lacks an antigen binding domain, and methods for using the recombinant stress response polypeptide to elicit an immune response, for example an anti-tumor response, in a subject.

5/3,AB/35 (Item 17 from file: 654)
DIALOG(R)File 654:US Pat.Full.

5419254
Derwent Accession: 1997-165035
Utility
C/ %Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James E., New York, NY
Hartl, F. Ulrich, Munich, DE
Hoe, Mee H., New York, NY
Houghton, Alan, New York, NY
Takeuchi, Yoshizumi, Kobe, JP
Mayhew, Mark, Tarrytown, NY
Assignee: Sloan Kettering Institute for Cancer Research (02), New York, NY
Sloan-Kettering Institute for Cancer Research (Code: 01305)
Examiner: Housel, James (Art Unit: 168)
Assistant Examiner: Brown, Stacy S.
Law Firm: Kenyon & Kenyon

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6641812	A	20031104	US 2001794529	20010227
Division	Pending			US 11645	

Fulltext Word Count: 9759

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.

5/3,AB/36 (Item 18 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005385982
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James, INV
Hartl, F., INV
Hoe, Mee, INV
Houghton, Alan, INV
Takeuchi, Yoshizumi, INV
Mayhew, Mark, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030185843	A1	20031002	US 2002171734	20020613
Continuation	PENDING			US 2000636295	20000810
Continuation	PENDING			US 9811645	19980213
A371	PENDING			WO 96US13363	19960816

Provisional	US 60-2490	19950818
Provisional	US 60-2479	19950818

Fulltext Word Count: 11925

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers

5/3,AB/37 (Item 19 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005385981
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: Rothman, James, INV
Hartl, F., INV
Hoe, Mee, INV
Houghton, Alan, INV
Takeuchi, Yoshizumi, INV
Mayhew, Mark, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030185842	A1	20031002	US 2002170713	20020613
Continuation	PENDING			US 9811645	19980213
A371	PENDING			WO 96US13363	19960816
Provisional				US 60-2490	19950818
Provisional				US 60-2479	19950818

Fulltext Word Count: 12054

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers

5/3,AB/38 (Item 20 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005367910
Derwent Accession: 2002-171706
Uses of the %heat% %shock% %protein% gp96
Inventor: Singh-Jasuja, Harpreet, INV
Schild, Hansjorg, INV
Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030175249	A1	20030918	US 2003338115	20030107
Continuation	UNKNOWN			WO 2001EP7864	20010709
Priority				DE 10033245	20000710

Fulltext Word Count: 7045

Abstract:
In a method for labeling or activating antigen-presenting cells (APCs) the APCs are contacted with gp molecules that do not carry interesting antigens.

The APCs are selected from the group consisting of dendritic cells, monocytes, macrophages, B cells and peritoneal exudate cells. Before the activation these APCs can be loaded with antigens and used in a method for inducing immune response or in tumor therapy.

5/3,AB/39 (Item 21 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005256656
Derwent Accession: 2003-156765
Membrane-resident steroid receptors and methods of use thereof
Inventor: Joel Rothman, INV
Erin Newman-Smith, INV
Gina Broitman-Maduro, INV
Assignee: The Regents of the University of California (02)
Correspondence Address: QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030108987	A1	20030612	US 2002153398	20020521
Provisional				US 60-292553	20010521

Fulltext Word Count: 25357

Abstract:
This invention pertains to the discovery that DPR-1 encodes a putative nuclear hormone receptor (NHR) that, based on gene reporter studies, is expressed in the endoderm throughout the life of the worm. NHR family members are transcriptional regulators that are activated when bound to their small lipophilic ligands such as steroids. While some NHRs are localized to the nucleus, others are cytoplasmic in the absence of ligand and translocate to the nucleus upon ligand binding. Once in the nucleus, they bind target sequences and regulate gene expression.

5/3,AB/40 (Item 22 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005229870
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: James Rothman, INV
F. Hartl, INV
Mee Hoe, INV
Alan Houghton, INV
Yoshizumi Takechi, INV
Mark Mayhew, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date

Main Patent	US 20030082198	A1	20030501	US 2001794832	20010227
Division	PENDING			US 9811645	19980213
A371	UNKNOWN			WO 96US13363	19960816
Provisional				US 60-2490	19950818
Provisional				US 60-2479	19950818

Fulltext Word Count: 11140

Abstract:
Administration of expressible polynucleotides encoding eukaryotic %heat% %shock% %proteins% to mammalian cells leads to the stimulation of an immune response to antigens present in those cells. This makes it possible to stimulate an immune response to target antigens, including target tumor antigens or antigens associated with an infectious disease, without having to isolate a unique antigen or antigen-associated %heat% %shock% %protein% for each target antigen by administering to a mammalian subject or to a group of mammalian cells containing the antigen, an expressible polynucleotide encoding a %heat% %shock% %protein%. The expressed %heat% %shock% %protein% may have the same structure as native %heat% %shock% %proteins%, or may be a modified form adapted to control the trafficking of the expressed %heat% %shock% %protein% within the cells

5/3,AB/41 (Item 23 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005229869
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: James Rothman, INV
F. Hartl, INV
Mee Hoe, INV
Alan Houghton, INV
Yoshizumi Takeuchi, INV
Mark Mayhew, INV
Correspondence Address: KENYON & KENYON, One Broadway, New York, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030082197	A1	20030501	US 2001794529	20010227
Division	PENDING			US 9811645	19980213
A371	UNKNOWN			WO 96US13363	19960816

Fulltext Word Count: 11234

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers

5/3,AB/42 (Item 24 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005211726
Derwent Accession: 2003-313086
Multivalent protein conjugate with multiple ligand-binding domains of receptors
Inventor: Shengjiang Liu, INV
Jean-Francois Martini, INV

Dayou Liu, INV
Correspondence Address: WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030064053	A1	20030403	US 2002232838	20020830
Provisional				US 60-316718	20010831

Fulltext Word Count: 22620

Abstract:
The present invention provides compositions and methods for treating abnormal cell proliferation and for regulating angiogenesis. In particular, multivalent protein conjugates (MVPs) are constructed to include multiple ligand-binding domains of different receptors and utilized to target multiple, different ligands that are involved in regulation of cell growth and neovascularization. The MVPs of the present invention can be used to treat various conditions associated with abnormal cell proliferation and angiogenesis such as cancer and cardiovascular disorders, as well as to promote wound healing.

5/3,AB/43 (Item 25 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005169840
Derwent Accession: 2003-438974
DNA-based analog neural networks
Inventor: Allen Mills, INV
Correspondence Address: VENABLE, BAETJER, HOWARD & CIVILETTI, L.L.P., P.O. Box 34385, Washington, DC, 20043-9998, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030022164	A1	20030130	US 2000741179	20001221
CIP	PENDING			US 98129958	19980806
Provisional				US 60-239263	20001012

Fulltext Word Count: 25471

Abstract:
This invention is an oligomer-based analog neural network (ANN) comprising weight and saturation oligomers, the concentrations of which are selected such that activation of the ANN by a set of input oligomers generates a set of output oligomers, the sequences and relative concentrations of which are dependent on the sequences and relative concentrations of the input oligomers. The invention further includes methods for using such an ANN for solving any problems amenable to solution by a trained neural network. A preferred embodiment of the claimed invention is a DNA-based ANN that accepts cDNA molecules as inputs and analyzes the gene expression profile of the cells from which the cDNA is derived. The DNA-based ANN is typically trained with a computer to identify the weights giving accurate mapping of the inputs to the outputs; and the concentrations of weight oligomers of the DNA-based ANN are then selected accordingly.

5/3,AB/44 (Item 26 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005169470
Derwent Accession: 1997-165035
%Heat% %shock% %protein%-based vaccines and immunotherapies
Inventor: James Rothman, INV
F. Hartl, INV
Mee Hoe, INV
Alan Houghton, INV
Yoshizumi Takechi, INV
Mark Mayhew, INV
Correspondence Address: KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030021794	A1	20030130	US 2001794517	20010227
Division	PENDING			US 9811645	19980213
A371	UNKNOWN			WO 96US13363	19960816
Provisional				US 60-2490	19950818
Provisional				US 60-2479	19950818

Fulltext Word Count: 11648

Abstract:
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heart shock protein in combination with one or more defined target antigens. These methods and compositions be used in the treatment of infectious diseases and cancers.

5/3,AB/45 (Item 27 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005140680
Derwent Accession: 2002-479659
Therapeutic formulations using %heat% %shock%/stress %protein%-peptide complexes
Inventor: Pramod Srivastava, INV
Assignee: University of Connecticut Health Center (02)
Correspondence Address: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20020192230	A1	20021219	US 2002126368	20020419
Continuation	PENDING			WO 2001US28840	20010917
Provisional				US 60-232779	20000915

Fulltext Word Count: 51282

Abstract:
The present invention relates to methods for making compositions comprising %heat% %shock% %proteins% or alpha (2) macroglobulin ("[small alpha, Greek]2M"), which compositions are immunogenic against a type of cancer or an agent of an infectious disease, and the compositions produced by the methods described herein. The invention further relates to methods for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. Specifically, the present invention provides a method of eliciting an immune response comprise administering to an individual a composition made by mixing an amount of a purified first complex

comprising a first %heat% %shock% %protein% or [small alpha, Greek]2M complexed to a peptide which displays antigenicity of an antigen of said type of cancer or antigenicity of an antigen of an agent of said infectious disease; and an equal or greater amount of a second %heat% %shock% %protein% or [small alpha, Greek]2M that is not complexed in vitro to a peptide which displays antigenicity of an antigen of said type of cancer or antigenicity of an antigen of an agent of said infectious disease, respectively; and is not in the form of a complex, said complex having been isolated as a complex from cancerous tissue of said type of cancer or cells infected with said agent of infectious disease, respectively. Optionally, the methods further comprise administering antigen presenting cells sensitized with hsp-peptide or [small alpha, Greek]2M-peptide complexes comprising peptides antigenic to cancer cells or to an agent of an infectious disease

?

5/3,AB/46 (Item 28 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005135609
Derwent Accession: 1996-209189
The use of %heat% %shock% %protein% 70 preparations in vaccination against cancer and infectious disease
Inventor: Pramod Srivastava, INV
Assignee: Mount Sinai School of Medicine of New York University (02)
Correspondence Address: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20020187159	A1	20021212	US 2002180562	20020625
Division	PENDING			US 99454734	19991206
Continuation	US 5997873			US 94180685	19940113

Fulltext Word Count: 7393

Abstract:
The use of cognate %heat% %shock% %protein% 70-peptide complex to elicit an immune response against cancer and viral, %bacterial% and other infectious agents

5/3,AB/47 (Item 29 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005130785
Derwent Accession: 1996-209189
Use of %heat% %shock% %protein% 70 preparations in vaccination against cancer and infectious disease
Inventor: Pramod Srivastava, INV
Assignee: Mount Sinai School of Medicine of New York University (02)
Correspondence Address: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20020182220	A1	20021205	US 2002180592	20020625
Division	PENDING			US 99454734	19991206
Continuation	US 5997873			US 94180685	19940113

Fulltext Word Count: 7294

Abstract:
The use of cognate %heat% %shock% %protein% 70-peptide complex to elicit an immune response against cancer and viral, %bacterial% and other infectious agents

5/3,AB/48 (Item 30 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005125777
Derwent Accession: 2003-298777
Polypeptide that interacts with %heat% %shock% %proteins%
Inventor: Winston Patterson, INV
Carol Ballinger, INV
Assignee: Board of Regents, The University of Texas System (02), Austin, TX

, 78701, US, 201 West Seventh Street
Correspondence Address: MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN, 55458, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20020177212	A1	20021128	US 200113939	20011207
CIP	PENDING			US 2000573473	20000517
Provisional				US 60-134433	19990517

Fulltext Word Count: 30497

Abstract:
An isolated polypeptide having negative regulating activity for a %heat% %shock% %protein% is provided. Also provided is an isolated nucleic acid encoding the polypeptide of the invention, methods for identifying inhibitors of the polypeptide and recombinant preparation of the polypeptide. Also provided are compositions such as inhibitor compositions

5/3,AB/49 (Item 31 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005064417
Derwent Accession: 2002-575225
Methods and compositions for protection against bovine viral deseases
Inventor: Subramaniam Srikumaran, INV
Assignee: The Board of Regents of the University of Nebraska (2)
Correspondence Address: SENNIGER POWERS LEAVITT AND ROEDEL, ONE METROPOLITAN SQUARE 16TH FLOOR, ST LOUIS, MO, 63102, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20020119163	A1	20020829	US 20013907	20011102
Provisional				US 60-245970	20001103

Fulltext Word Count: 10128

Abstract:
The present invention relates to methods and compositions for eliciting an immune response against bovine viral epitopes. The methods comprise combining at least one %heat% %shock% %protein% with at least one bovine viral epitope to form a purified epitope/%heat% %shock% %protein% %complex% and administration of an immune system stimulating amount of the purified epitope/%heat% %shock% %protein% %complex%. The compositions comprise, a purified epitope/%heat% %shock% %protein% %complex% comprising at least one bovine viral epitope complexed with at least one %heat% %shock% %protein%, and a pharmaceutically acceptable carrier, diluent or excipient

5/3,AB/50 (Item 32 from file: 654)
DIALOG(R)File 654:US Pat.Full.

0005047938
Derwent Accession: 1998-495549
Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
Inventor: Frederic Henot, INV
Thierry Legon, INV
Jean Duchateau, INV
Genevieve Servais, INV

Correspondence Address: MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN , 55402-0903, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20020102632	A1	20020801	US 2001891148	20010625
CIP	PATENTED			US 99380548	19991028
Priority				BE 97199	19970305

Fulltext Word Count: 12673

Abstract:
The present invention is related to a process for obtaining a composition comprising peptides bound to one or more %heat% %shock% %protein%(s) and for possibly recovering from said composition the bound peptides, wherein the peptides resulting from a previously in-vitro hydrolysis of at least one immunogenic and antigenic macromolecular structure, are mixed in-vitro with one or more %heat% %shock% %protein% (s).

The present invention is also related to the compositions obtained by said process

5/3,AB/51 (Item 33 from file: 654)
DIALOG(R)File 654:US Pat.Full.

4883545
Derwent Accession: 2000-097545
Utility
C/ Methods and kits for discovery of RNA-binding compounds ; REPORTER MOLECULE AND RNA TARGET MOLECULE, BOTH CARRYING A FLUORESCENT OR CHROMOGENIC GROUP, PLACED IN CLOSE PROXIMITY TO EACH OTHER; ADDITION OF TEST COMPOUND INHIBITS THEIR BINDING AND INCREASES FLUORESCENCE; DRUG SCREENING
Inventor: Karn, Jonathan, Little Shelford, GB
Prescott, Catherine Denise, Cambridge, GB
Assignee: Ribotargets, Ltd. (03), Cambridge, GB
RiboTargets Ltd GB (Code: 54465)
Examiner: Jones, W. Gary (Art Unit: 165)
Assistant Examiner: Chakrabarti, Arun Kr.
Law Firm: Palmer & Dodge, LLP
Combined Principal Attorneys: Williams, Kathleen M.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6573045	A	20030603	US 99325601	19990603

Fulltext Word Count: 25550

Abstract:
The invention relates to a solution-based assay for identifying RNA binding compounds, based on competition. The assay comprises a reporter molecule carrying a fluorescent or chromogenic group that can form a one-to-one complex with an RNA target molecule carrying a second fluorescent or chromogenic group in such a way that the two groups are in sufficient proximity for fluorescence resonance energy transfer and/or quenching to take place. Addition of a compound-to-be-tested prevents formation of the complex and thereby increases the fluorescence of the RNA target and/or reporter molecules relative to the signal obtained in the absence of the test compound. The invention also provides for quantitative screening methods and kits are also included.

5/3,AB/52 (Item 34 from file: 654)

DIALOG(R)File 654:US Pat.Full.

4753431
Derwent Accession: 1999-580417
Utility
C/ Methods for using %heat% %shock% %proteins%
Inventor: Wallen, Erik, Albuquerque, NM
Moseley, Pope L., Albuquerque, NM
Assignee: University of New Mexico (02), Albuquerque, NM
New Mexico, University of (Code: 14014)
Examiner: Jones, Dwayne C. (Art Unit: 164)
Assistant Examiner: Delacroix-Muirhei, C.
Law Firm: Jagtiani + Guttag

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6455493	A	20020924	US 99276468	19990325
CIP	US 5981706	A		US 97986234	19971205
CIP	US 6066716	A		US 97934139	19970919
CIP	US 5747332	A		US 96717239	19960920

Fulltext Word Count: 3631

Abstract:
The present invention provides a %heat% %shock% %protein% immunotoxin comprising: at least a fragment of a %heat% %shock% %protein%, the fragment being capable of being bound by an immune cell; and a toxin bound to the fragment. The present invention also provides a method for decreasing the number of immune cells in an individual using the %heat% %shock% %protein% immunotoxins of the present invention. In addition, the present invention provides a method for decreasing the number of immune cells in an organ using the %heat% %shock% %protein% immunotoxins of the present invention.

5/3,AB/53 (Item 35 from file: 654)
DIALOG(R)File 654:US Pat.Full.

4748665
Derwent Accession: 2000-317604
Utility
CERTIFICATE OF CORRECTION
C/ Methods for generating antigen-reactive T cells in vitro
; INCUBATING T-CELLS AND ANTIGEN PRESENTING CELLS IN VITRO WITH PURIFIED COMPLEX OF %HEAT% %SHOCK% %PROTEIN% AND ANTIGEN; GENERATING CD4 CELLS; IMMUNOTHERAPY, ANTICARCINOGENIC AGENTS
Inventor: Srivastava, Pramod K., Avon, CT
Assignee: University of Conneticut Health Center (02), Farmington, CT
Connecticut, University of (Code: 02814)
Examiner: Bansal, Geetha P. (Art Unit: 162)
Law Firm: Pennie & Edmonds LLP

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6451316	A	20020917	US 98166401	19981005

Fulltext Word Count: 20359

Abstract:
The present invention provides methods for generating antigen-reactive T cells in vitro comprising priming immune cells and incubating the primed immune cells in vitro with a non-covalent complex of an %heat% %shock% %protein% and an antigenic molecule. The present invention further relates to methods for generating antigen-reactive CD4+ T cells

for immunotherapy. Methods and compositions are also disclosed for the treatment and prevention of cancer or infectious disease in a subject comprising administering to the subject MHC matched antigen-reactive T cells that are generated in vitro by the present methods.

5/3,AB/54 (Item 36 from file: 654)
DIALOG(R)File 654:US Pat.Full.

4691454
Derwent Accession: 1998-456757
Utility
C/ Methods and compositions for eliciting an immune response with hsp90-peptide complexes
; %HEAT% %SHOCK% %PROTEIN% %COMPLEX% FOR IMMUNOLOGY
Inventor: Srivastava, Pramod K., Riverdale, NY
Chandawarkar, Rajiv Y., Mineola, NY
Assignee: Fordham University (02), Bronx, NY
Fordham University (Code: 47477)
Examiner: Bansal, Geetha P. (Art Unit: 162)
Law Firm: Pennie & Edmonds LLP

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6399070	A	20020604	US 99440177	19991115
Division	US 6017540	A		US 97796319	19970207

Fulltext Word Count: 19593

Abstract:
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a %heat% %shock% %protein% (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.

5/3,AB/55 (Item 37 from file: 654)
DIALOG(R)File 654:US Pat.Full.

4394839
Derwent Accession: 1998-240805
Utility
C/ Methods for generating cytotoxic T cells in vitro
; GENERATING TOXIC LYMPHOCYTES PREFERENTIAL TO ANTIGENIC CELLS; SUBJECTING VIABLE ANIMAL ANTIGENIC CELLS TO OSMOTIC SHOCK, IRRADIATING, CULTURING THE ANTIGENIC CELLS WITH IMMUNE CELLS, RECOVERING PREFERENTIALLY TOXIC LYMPHOCYTES
Inventor: Srivastava, Pramod K., Riverdale, NY
Binder, Robert, Bronx, NY
Blachere, Nathalie E., Bronx, NY
Assignee: Fordham University (02), Bronx, NY
Fordham University (Code: 47477)

Examiner: Cunningham, Thomas M. (Art Unit: 164)
Assistant Examiner: Lubet, Martha T.
Law Firm: Pennie & Edmonds LLP

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6130087	A	20001010	US 96726967	19961007

Fulltext Word Count: 13607

Abstract:
The present invention provides methods for generating antigen-reactive cytotoxic T cells in vitro comprising culturing immune cells and antigenic cells that have at least one MHC allele in common (and preferably, are syngeneic), in which the antigenic cells have been treated according to the methods of the invention. The antigenic cells are treated by subjecting them to osmotic shock followed by irradiation. As a result, a subset of T cells are activated and mature into antigen-reactive cytotoxic T cells. The effectiveness of the procedure may be enhanced by repeated restimulations and/or the addition of %heat% %shock% %protein%-peptide complexes. Methods and compositions are also disclosed for the treatment and prevention in a subject of cancer or infectious disease comprising administering to the subject matched cytotoxic T cells that are generated in vitro by the present methods.

5/3,AB/56 (Item 38 from file: 654)
DIALOG(R)File 654:US Pat.Full.

4284377
Derwent Accession: 1997-202007
Utility
C/ Therapeutic and prophylactic methods using %heat% %shock% %proteins%
Inventor: Srivastava, Pramod K., Riverdale, NY
Assignee: Fordham University (02), Bronx, NY
Fordham University (Code: 47477)
Examiner: Huff, Sheela (Art Unit: 162)
Assistant Examiner: Bansal, Geetha P.
Law Firm: Pennie & Edmonds LLP

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6030618	A	20000229	US 96711918	19960910
CIP	US 5935576	A		US 95527547	19950913

Fulltext Word Count: 14691

Abstract:
The present invention relates to immunogenic complexes of %heat% %shock% %proteins% (hsp) noncovalently bound to exogenous antigenic molecules which when administered to an individual elicit specific immunological responses in the host. Methods of prevention and treatment of cancer and infectious disease are provided.

5/3,AB/57 (Item 39 from file: 654)
DIALOG(R)File 654:US Pat.Full.

4230253
Derwent Accession: 1999-394912
Utility
REASSIGNED
C/ Methods for synthesizing %heat% %shock% %protein% complexes

; %BIND%%ING H%%EAT SHO%%CK P%%ROTEI%%N TO DE%NATURED PROTEIN MATRIX, ADDING COMPLEXING SOLUTION CONTAINING A PEPTIDE TO ELUTE A %HEAT% %SHOCK% %PROTEIN%-PEPTIDE %COMPLEX%; PRODUCTION OF ANTICARCINOGENIC/ANTITUMOR PEPTIDE-BASED VACCINES
Inventor: Wallen, Erik S., Albuquerque, NM
Moseley, Pope L., Albuquerque, NM
Assignee: University of New Mexico (02), Albuquerque, NM
New Mexico, University of (Code: 14014)
Examiner: Tsang, Cecilia J. (Art Unit: 164)
Assistant Examiner: Delacroix-Muirheid, C.
Law Firm: Jagtianai & Associate

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5981706	A	19991109	US 97986234	19971205
CIP	US 5747332	A		US 96717239	19960920
	Pending			US 97934139	19970919

Fulltext Word Count: 3452

Abstract:
The present invention provides a method for synthesizing %heat% %shock% %protein%-peptide complexes comprising the steps of: adding a shock protein to a denatured protein matrix to bind the %heat% %shock% %protein% to the denatured protein matrix; and adding a complexing solution comprising a peptide to elute a %heat% %shock% %protein%-peptide %complex%. The present invention also provides a %heat% %shock% %protein% -peptide %complex% synthesized by the method of the invention. In addition the present invention provides an apparatus for synthesizing %heat% %shock% %protein%-peptide complexes comprising a %heat% %shock% %protein% %complex% bound to a denatured protein matrix.

5/3,AB/58 (Item 40 from file: 654)
DIALOG(R)File 654:US Pat.Full.

4209023
Derwent Accession: 1995-336815
Utility
REASSIGNED
C/ Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
; COMPLEX OF A MAMMALIAN STRESS PROTEIN NONCOVALENTLY ASSOCIATED WITH A PEPTIDE THAT IS PRESENT IN A EUKARYOTIC CELL INFECTED WITH SAID PATHOGEN BUT NOT PRESENT IN SAID CELL WHEN SAID CELL IS NOT INFECTED WITH SAID PATHOGEN
Inventor: Srivastava, Pramod K., Riverdale, NY
Assignee: Mount Sinai School of Medicine of the City University of New York (02), New York, NY
Mount Sinai School of Medicine of City Univ of New York (Code: 57466)
Examiner: Hutzell, Paula K. (Art Unit: 162)
Assistant Examiner: Bansal, Geetha P.
Law Firm: Pennie & Edmonds LLP

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5961979	A	19991005	US 94210421	19940316

Fulltext Word Count: 19940

Abstract:
Disclosed is a family of vaccines that contain stress protein-peptide complexes which when administered to a mammal are operative at initiating

in the mammal cytotoxic T cell responses against preselected intracellular pathogens. Also disclosed are methodologies for preparing and administering vaccines containing stress protein-peptide complexes.

5/3,AB/59 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01095338
ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO TRAIL RECEPTORS
ANTICORPS SE FIXANT DE FACON IMMUNOSPECIFIQUE A DES RECEPTEURS TRAIL
Patent Applicant/Assignee:
HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
SALCEDO Theodora, 403 McCool Avenue East, Syracuse, NY 13057, US, US (Residence), US (Nationality), (Designated only for: US)
RUBEN Steven M, 19420 Pyrite Lane, Brookeville, MD 20833, US, US (Residence), US (Nationality), (Designated only for: US)
ROSEN Craig A, 22400 Rolling Hill Lane, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)
ALBERT Vivian A, 13710 Mills Farm Road, Rockville, MD 20850, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
DAVIS James H (et al) (agent), 9410 Key West Avenue, Rockville, MD 20850, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200416753 A2 20040226 (WO 0416753)
Application: WO 2003US25457 20030815 (PCT/WO US03025457)
Priority Application: US 2002403382 20020815; US 2002425730 20021113; US 2003468050 20030506
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 143502

English Abstract
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.

French Abstract
L'invention concerne des anticorps et des molecules apparentees se fixant de facon immunospecifique au recepteur TRAIL, TR4. Ces anticorps peuvent etre, par exemple, mis en application pour la prevention et le traitement de cancers ou d'autres maladies proliferatives. Elle concerne egalement des molecules d'acides nucleiques codant des anticorps anti-TR4, des vecteurs et des cellules hotes contenant ces acides nucleiques et des methodes servant a les produire. Elle concerne egalement des methodes et

des compositions servant a prevenir, detecter, diagnostiquer, traiter ou ameliorer un trouble ou une maladie, en particulier, le cancer ou d'autres maladies hyperproliferatives, ce qui consiste a administrer a un animal, de preference un humain, une quantite efficace d'un ou plusieurs anticorps ou fragments ou variantes de ces anticorps, ou des molecules apparentees, se fixant de maniere immunospecifique au recepteur TRAIL, TR4.

5/3,AB/60 (Item 2 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01088535
PROTEIN COMPLEXES OF CELLULAR NETWORKS UNDERLYING THE DEVELOPMENT OF CANCER AND OTHER DISEASES
COMPLEXES DE PROTEINIQUES DE RESEAUX CELLULAIRES FONDANT LE DEVELOPPEMENT DU CANCER ET D'AUTRES MALADIES
Patent Applicant/Assignee:
CELLZOME AG, Meyerhofstrasse 1, 69117 Heidelberg, DE, DE (Residence), DE (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
MERINO Alejandro, Kleine Mantelgasse 21, 69117 Heidelberg, DE, DE (Residence), CL (Nationality), (Designated only for: US)
BOUWMEESTER Tewis, Bergstr. 1, 69120 Heidelberg, DE, DE (Residence), NL (Nationality), (Designated only for: US)
BAUER Andreas, Dammweg 9, 69123 Heidelberg, DE, DE (Residence), DE (Nationality), (Designated only for: US)
DREWES Gerard, Schiffgasse 6, 69117 Heidelberg, DE, DE (Residence), NL (Nationality), (Designated only for: US)
MARZIOCH Martina, Berghalde 34, 69126 Heidelberg, DE, DE (Residence), DE (Nationality), (Designated only for: US)
KRUSE Ulrich, Frankenweg 32, 69221 Dossenheim, DE, DE (Residence), DE (Nationality), (Designated only for: US)
SUPERTI-FURGA Giulio, Muhldamm 7, 69118 Heidelberg, DE, DE (Residence), IT (Nationality), (Designated only for: US)
EBERHARD Dirk, Daniel-Hartmann-Str. 7, 69256 Mauer, DE, DE (Residence), DE (Nationality), (Designated only for: US)
RUFFNER Heinz, Reilsheimer Str. 42/1, 69245 Bammental, DE, DE (Residence), CH (Nationality), (Designated only for: US)
HOBSON Scott, Bismarckstr. 47, 69198 Schriesheim, DE, DE (Residence), US (Nationality), (Designated only for: US)
HELFTENBEIN Gerd, Nieder-Ohmener Str. 16, 35329 Gmunden, DE, DE (Residence), DE (Nationality), (Designated only for: US)
CRUCIAT Cristina, Taunusstr. 10, 64289 Darmstadt, DE, DE (Residence), DE (Nationality), (Designated only for: US)
Legal Representative:
HUHN Michael (agent), Isenbruck, Bosl, Horschler, Wichmann, Huhn, Theodor-Heuss-Analge 12, 68165 Mannheim, DE,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200409622 A2 20040129 (WO 0409622)
Application: WO 2003EP7835 20030718 (PCT/WO EP03007835)
Priority Application: EP 200216109 20020719; EP 200216128 20020719; EP 200216123 20020719; EP 200216111 20020719; EP 200216427 20020722
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 152462

English Abstract

The present invention relates to protein complexes involved in cellular processes which have been shown to be critical for the development of various forms of cancer, component proteins of the said complexes, fragments and derivatives of the component proteins, and antibodies specific to the complexes. The present invention also relates to methods for use of the complexes and their interacting proteins in, inter alia, screening, diagnosis, and therapy, as well as to methods of preparing the complexes.

French Abstract

La presente invention concerne des complexes proteiniques qui entrent en jeu dans des processus cellulaires qui se sont averes critiques pour le developpement de diverses formes de cancer, des proteines composant de ces complexes, des fragments et des derives de ces proteines composant et, des anticorps specifiques de ces complexes. Cette invention concerne aussi des techniques d'utilisation de ces complexes et leur proteines d'interaction dans la recherche, le diagnostic et la therapie, entre autres domaines d'utilisation, ainsi que des techniques de preparation de ces complexes.

5/3,AB/61 (Item 3 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01064986

USE OF HEAT SHOCK PROTEINS TO ENHANCE EFFICACY OF ANTIBODY THERAPEUTICS

UTILISATION DE PROTEINES DU STRESS EN VUE D'AMELIORER L'EFFICACITE DE LA THERAPEUTIQUE ANTICORPS

Patent Applicant/Assignee:
UNIVERSITY OF CONNECTICUT HEALTH CENTER, 263 Farmington Avenue, Farmington, CT 06030-5355, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
SRIVASTAVA Pramod K, 70 Pheasant Run, Avon, CT 06001, US, US (Residence), IN (Nationality), (Designated only for: US)
Legal Representative:
ANTLER Adriane M (et al) (agent), Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US,

Patent and Priority Information (Country, Number, Date):
Patent: WO 200392624 A2-A3 20031113 (WO 0392624)
Application: WO 2003US13967 20030502 (PCT/WO US03013967)
Priority Application: US 2002377483 20020502
Designated States: AU CA CN IL IN JP KP KR NO RU SG US
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
Publication Language: English
Filing Language: English
Fulltext Word Count: 20519

English Abstract

The present invention relates to methods and pharmaceutical compositions useful for the prevention and treatment of any disease wherein the treatment of such disease would be improved by an enhanced immune response, such as infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), or neurodegenerative or amyloid diseases. In particular, the contemplated invention is directed to method comprising the administration of heat shock/stress proteins (HSPs) or HSP complexes alone or in combination with each other, in combination with the administration of an immunoreactive reagent. The invention also provides pharmaceutical compositions comprising one or more HSPs or HSP complexes in combination with an immunoreactive reagent. Additionally, the invention contemplates the use of the methods and compositions of the invention to enhance or improve passive immunotherapy and effector cell function.

French Abstract

L'invention concerne des procedes et des compositions pharmaceutiques utilises pour la prevention et le traitement de maladies pour lesquelles le traitement serait ameliore par une reponse immune accrue, telles que

maladies infectieuses, maladies neoplastiques primaires et metastatiques (c'est-a-dire cancereuses) ou maladies neurodegeneratives ou amyloides. En particulier, l'invention concerne un procede comprenant l'administration de proteines du stress (HSP) ou de complexes HSP, seuls ou en combinaison entre eux, en combinaison avec l'administration d'un reactif immunologique. L'invention concerne en outre des compositions pharmaceutiques comprenant un ou plusieurs HSP ou complexes HSP, en combinaison avec un reactif immunologique. De plus, l'invention concerne l'utilisation des procedes et compositions de l'invention, en vue d'accroitre ou d'ameliorer l'immunotherapie passive et la fonction cellulaire effectrice.

5/3,AB/62 (Item 4 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01042832
METHODS AND PRODUCTS BASED ON OLIGOMERIZATION OF STRESS PROTEINS
METHODES FONDEES SUR L'OLIGOMERISATION DE PROTEINES DE STRESS ET PRODUITS ASSOCIES
Patent Applicant/Assignee:
ANTIGENICS INC, 630 Fifth Avenue, Suite 2100, New York, NY 10111, US, US (Residence), US (Nationality), (For all designated states except: US)
UNIVERSITY OF CONNECTICUT HEALTH CENTER, 263 Farmington Avenue, Farmington, CT 06030-6207, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
ZABRECKY James R, 18 Arlington Road, Waltham, MA 02453, US, US (Residence), US (Nationality), (Designated only for: US)
LIU Chuanliang, 23 Victor Street #23, Haverhill, MA 01832, US, US (Residence), CN (Nationality), (Designated only for: US)
MONKS Stephen A, 58 Willow Avenue, Somerville, MA 02144, US, US (Residence), AU (Nationality), (Designated only for: US)
WASSERMAN Andrew, 707 Johnson Street, North Andover, MA 01845, US, US (Residence), US (Nationality), (Designated only for: US)
SRIVASTAVA Pramod K, 70 Pheasant Run, Avon, CT 06001, US, US (Residence), IN (Nationality), (Designated only for: US)
Legal Representative:
ANTLER Adriane M (et al) (agent), Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200372595 A2 20030904 (WO 0372595)
Application: WO 2003US6298 20030228 (PCT/WO US0306298)
Priority Application: US 2002361257 20020228
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 52883

English Abstract
In one aspect, the invention provides methods for determining the biological activity of heat shock proteins or heat shock protein-peptide complexes based on the ATPase activity or the multimeric structure of the heat shock proteins or heat shock protein-peptide complexes, and methods for screening agents that modulate the biological activity of heat shock proteins or heat shock protein-peptide complexes. In another aspect, the invention provides complexes, compositions and methods for enhancing the immunogenicity of a heat shock protein or a complex comprising a heat shock protein and an antigenic molecule.

French Abstract
Dans l'un de ses aspects, l'invention concerne des methodes permettant de determiner l'activite biologique de proteines de choc thermique ou de complexes de proteines-peptides de choc thermique en fonction de l'activite ATPase ou de la structure multimere desdites proteines de choc thermique ou desdits complexes de proteines-peptides de choc thermique; et des methodes permettant de cribler des agents qui modulent l'activite biologique de ces proteines ou de ces complexes de proteines-peptides de choc thermique. Dans un autre aspect, l'invention concerne des complexes, des compositions et des methodes ameliorant l'immunogenicite d'une proteine de choc thermique ou d'un complexe comprenant une proteine de choc thermique et une molecule antigene.

5/3,AB/63 (Item 5 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01039082
MODULATION OF IMMUNE RESPONSE BY NON-PEPTIDE BINDING STRESS RESPONSE POLYPEPTIDES
MODULATION DE REPONSE IMMUNITAIRE PAR DES POLYPEPTIDES DE REPONSE A UN STRESS SE LIANT A DES NON PEPTIDES
Patent Applicant/Assignee:
DUKE UNIVERSITY, Office of Science and Technology, P.O. Box 90083, Durham, NC 27708, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
NICCHITA Christopher, 115 Pinecrest Road, Durham, NC 27705, US, US (Residence), US (Nationality), (Designated only for: US)
BAKER-LEPAIN Julie, 6 Spruce Knob Court, Durham, NC 27705, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
TAYLOR Arles A Jr (agent), Jenkins & Wilson, P.A., Suite 1400, University Tower, 3100 Tower Boulevard, Durham, NC 27707, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200368941 A2 20030821 (WO 0368941)
Application: WO 2003US4631 20030213 (PCT/WO US0304631)
Priority Application: US 2002356293 20020213
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 29577

English Abstract
A recombinant stress response polypeptide that lacks an antigen binding domain, and methods for using the recombinant stress response polypeptide to elicit an immune response, for example an anti-tumor response, in a subject.

French Abstract
L'invention concerne un polypeptide recombinant de reponse a un stress ne comportant pas de domaine de liaison a un antigene, ainsi que des procedes d'utilisation de ce polypeptide permettant de favoriser une reponse immunitaire, par exemple une reponse antitumorale, chez un individu.

5/3,AB/64 (Item 6 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

01033764
MODULATION OF HEAT-SHOCK-PROTEIN-BASED IMMUNOTHERAPIES
MODULATION D'IMMUNO-THERAPIES BASEES SUR DES PROTEINES DE CHOC THERMIQUE
Patent Applicant/Assignee:
MOJAVE THERAPEUTICS INC, 22 Saw Mill River Road, Hawthorne, NY 10532, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
WIELAND Felix, Theaterstrasse 2a, 69112 Heidelberg, DE, DE (Residence), DE (Nationality), (Designated only for: US)
HARTL Franz-Ulrich, Schulstrasse 12, 82288 Kottgeisering, DE, DE (Residence), DE (Nationality), (Designated only for: US)
Legal Representative:
SOMERVILLE Deborah A (et al) (agent), Kenyon & Kenyon, One Broadway, New York, NY 10004, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200362262 A2 20030731 (WO 0362262)
Application: WO 2002US41373 20021224 (PCT/WO US0241373)
Priority Application: US 2001342570 20011226; US 2001343884 20011228; US 2002372620 20020412; US 2002399342 20020729; US 2002414834 20020928
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 29810

English Abstract
Methods and compositions are provided for modulating the immune response to an antigen based upon the finding that the cell surface protein CD40 is a mammalian heat shock protein (HSP) receptor. Cell surface CD40 mediates the binding, cell signaling, and uptake of hsp and particularly hsp with antigen bound thereto. Methods are provided for modulating hsp-antigen uptake and an immune response tot he antigen by altering CD40 expression, as well as utilizing CD40-binding fragments of mammalian hsp and muteins thereof for targeting antigens to CD40-expressing cells. Screening methods for agonists and antagonists of the CD40-hsp are also provided.

French Abstract
L'invention concerne des procedes et des compositions qui permettent de moduler la reponse immunitaire a un antigene, en fonction de la decouverte selon laquelle le CD 40 de la proteine de surface cellulaire est un recepteur de proteine de choc thermique de mammifere. Le CD 40 de surface cellulaire assure la mediation de la liaison, la signalisation cellulaire, et la capture de la proteine de choc chermique et en particulier de la proteine de choc thermique avec un antigene lie a cette derniere. L'invention concerne des procedes permettant de moduler la capture de l'antigene de la proteine de choc thermique et une reponse immunitaire a l'antigene en modifiant l'expression de CD40 ainsi qu'en utilisant des fragments de liaison de CD40 de la proteine de choc thermique de mammifere et des muteines de ces dernieres pour cibler des antigenes de cellules d'expression de CD40. L'invention traite aussi de procedes pour des agonistes et des antagonistes de l'interaction de la proteine de choc thermique et du CD40.

5/3,AB/65 (Item 7 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00992263

MULTIVALENT PROTEIN CONJUGATE WITH MULTIPLE LIGAND-BINDING DOMAINS OF RECEPTORS
CONJUGUES DE PROTEINES MULTIVALENTES AYANT DES DOMAINES DE LIAISON DE LIGAND MULTIPLES DE RECEPTEURS
Patent Applicant/Assignee:
ABMAXIS INC, Suites A & B, 453 Ravendale Drive, Mountain View, CA 94043, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
LIU Shengjiang, 535 Devonshire Court, Mountain View, CA 94043, US, US (Residence), US (Nationality), (Designated only for: US)
LIU Dayou, 655 South Fair Oaks Ave., Apartment K-208, Sunnyvale, CA 94086, US, US (Residence), CN (Nationality), (Designated only for: US)
MARTINI Jean-Francois, 200 Baltic Circle, Unit 226, Redwood City, CA 94065, US, US (Residence), FR (Nationality), (Designated only for: US)
Legal Representative:
CHEN Shirley (agent), Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200320906 A2-A3 20030313 (WO 0320906)
Application: WO 2002US27888 20020830 (PCT/WO US02027888)
Priority Application: US 2001316718 20010831
Parent Application/Grant:
Related by Continuation to: US 2001316718 20010831 (CIP)
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 19852

English Abstract
The present invention provides compositions and methods for treating abnormal cell proliferation and for regulating angiogenesis. In particular, multivalent protein conjugates (MVPs) are constructed to include multiple ligand-binding domains of different receptors and utilized to target multiple, different ligands that are involved in regulation of cell growth and neovascularization. The MVPs of the present invention can be used to treat various conditions associated with abnormal cell proliferation and angiogenesis such as cancer and cardiovascular disorders, as well as to promote wound healing.

French Abstract
L'invention concerne des compositions et des methodes de traitement d'une proliferation anormale de cellules et des methodes de regulation de l'angiogenese. En particulier, des conjugues de proteines multivalentes (PMV) sont prepares de facon a comprendre des domaines de liaison de ligand de differents recepteurs et sont utilises de facon a cibler de multiples ligands differents intervenant dans la regulation de la croissance des cellules ainsi que dans la neovascularisation. Lesdites proteines multivalentes peuvent etre utilisees dans le traitement de plusieurs etats pathologiques associes a une angiogenese ou a une proliferation de cellules anormale, tels qu'un cancer ou des troubles cardio-vasculaires. Lesdites proteines peuvent egalement etre utilisees pour favoriser la cicatrisation d'une lesion.

5/3,AB/66 (Item 8 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00962433
MEMBRANE-RESIDENT STEROID RECEPTORS AND METHODS OF USE THEREOF
RECEPTEURS STEROIDIENS DE MEMBRANE ET LEURS METHODES D'UTILISATION

Patent Applicant/Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, 12th Floor, 1111 Franklin Street, Oakland, CA 94607-5200, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
ROTHMAN Joel H, 445 Fellowship Road, Santa Barbara, CA 93109, US, US (Residence), US (Nationality), (Designated only for: US)
NEWMAN-SMITH Erin, 2760 Williams Way, Santa Barbara, CA 93105, US, US (Residence), US (Nationality), (Designated only for: US)
BROITMAN-MADURO Gina, 1227 Bath Street #1, Santa Barbara, CA 93101, US, US (Residence), CA (Nationality), (Designated only for: US)
Legal Representative:
QUINE Jonathan Alan (et al) (agent), Quine Intellectual Property Law Group, P.C., P.O. Box 458, Alameda, CA 94501, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200295405 A1 20021128 (WO 0295405)
Application: WO 2002US16231 20020521 (PCT/WO US0216231)
Priority Application: US 2001292553 20010521
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 22721

English Abstract
This invention pertains to the discovery that DPR-1 encodes a putative nuclear hormone receptor (NHR) that, based on gene reporter studies, is expressed in the endoderm throughout the life of the worm. NHR family members are transcriptional regulators that are activated when bound to their small lipophilic ligands such as steroids. While some NHRs are localized to the nucleus, others are cytoplasmic in the absence of ligand and translocate to the nucleus upon ligand binding. Once in the nucleus, they bind target sequences and regulate gene expression.
French Abstract
La presente invention se rapporte a la decouverte selon laquelle <I>DPR-1</I> code pour un recepteur hormonal nucleaire (NHR) reconnu, qui selon des etudes relatives a des genes rapporteurs, est exprime dans l'endoderme du ver durant toute sa vie. Les membres de la famille des recepteurs NHR sont des regulateurs de transcription qui sont actives lorsqu'ils sont lies a de petits ligands lipophiliques tels que des steroides. Alors que certains recepteurs NHR se trouvent dans le noyau, d'autres resident dans le cytoplasme en l'absence de ligands, et subissent une translocation vers le noyau lorsqu'ils se lient avec leur ligand. Des qu'ils se trouvent dans le noyau, ils se lient a des sequences cibles et regulent l'expression genique.

5/3,AB/67 (Item 9 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00909489
COMPOSITIONS FOR PROTECTION AGAINST BOVINE VIRAL DISEASES
PROCEDES ET COMPOSITIONS DE PROTECTION CONTRE DES MALADIES VIRALES DE BOVIDES
Patent Applicant/Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, 3835 Holdrege Street, Lincoln, NE 68588-0745, US, US (Residence), US (Nationality)
Inventor(s):
SRIKUMARAN Subramaniam, c/o The Board of Regents of the University of Nebraska, 3835 Holdrege Street, Lincoln, NE 68588-0745, US,
Legal Representative:
DOTY Kathryn J (et al) (agent), Senniger, Powers, Leavitt & Roedel, One

Metropolitan Square, 16th Floor, St. Louis, MO 63102, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200241921 A2-A3 20020530 (WO 0241921)
Application: WO 2001US45781 20011102 (PCT/WO US0145781)
Priority Application: US 2000245970 20001103
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 8881

English Abstract
The present invention relates to methods and compositions for eliciting an immune response against bovine viral epitopes. The methods comprise combining at least one %heat% %shock% %protein% with at least one bovine viral epitope to form a purified epitope/%heat% %shock% %protein% %complex% and administration of an immune system stimulating amount of the purified epitope/%heat% %shock% %protein% %complex%. The compositions comprise, a purified epitope/%heat% %shock% %protein% %complex% comprising at least one bovine viral epitope complexed with at least one %heat% %shock% %protein%, and a pharmaceutically acceptable carrier, diluent or excipient.

French Abstract
L'invention concerne des procedes et des compositions permettant de provoquer une reponse immune contre des epitopes viraux de bovides. Les procedes consistent a combiner au moins une proteine de choc thermique avec au moins un epitope viral de bovide afin de former un complexe purifie de proteine de choc thermique/epitope et a administrer une quantite immunostimulante du complexe purifie de proteine de choc thermique/epitope. Les compositions comprennent un complexe purifie de proteine de choc thermique/epitope constitue d'au moins un epitope viral de bovide complexe avec au moins une proteine de choc thermique, ainsi qu'un support, un diluant ou un excipient acceptable sur le plan pharmaceutique.

5/3,AB/68 (Item 10 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00900194
PROTEINS AND NUCLEIC ACIDS ENCODING SAME
PROTEINES ET ACIDES NUCLEIQUES CODANT LES MEMES
Patent Applicant/Assignee:
CURAGEN CORPORATION, 555 Long Wharf Drive, 11th floor, New Haven, CT 06511, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
EDINGER Shlomit, 766 Edgewood Avenue, New Haven, CT 06515, US, US (Residence), US (Nationality), (Designated only for: US)
GERLACH Valerie, 18 Rock Pasture Road, Branford, CT 06405, US, US (Residence), US (Nationality), (Designated only for: US)
MACDOUGALL John R, 117 Russell Street, Hamden, CT 06517, US, US (Residence), CA (Nationality), (Designated only for: US)
MALYANKAR Uriel M, 35 Averill Place, Branford, CT 06405, US, US (Residence), IN (Nationality), (Designated only for: US)
SMITHSON Glennda, 125 Michael Drive, Guilford, CT 06435, US, US (Residence), US (Nationality), (Designated only for: US)
MILLET Isabelle, 74 Carrington Avenue, Milford, CT 06460, US, US (Residence), US (Nationality), (Designated only for: US)
PEYMAN John A, 336 West Rock Avenue, New Haven, CT 06515, US, US (Residence), US (Nationality), (Designated only for: US)

STONE David J, 223 Whitehorn Drive, Guilford, CT 06437, US, US (Residence), US (Nationality), (Designated only for: US)
GUNTHER Erik, 34 Bryan Road, Branford, CT 06405, US, US (Residence), US (Nationality), (Designated only for: US)
ELLERMAN Karen, 87 Montoya Drive, Branford, CT, US, US (Residence), US (Nationality), (Designated only for: US)
SHIMKETS Richard A, 191 Leete Street, West Haven, CT, US, US (Residence), US (Nationality), (Designated only for: US)
PADIGARU Muralidhara, 71 Hampton Park, Branford, CT 06405, US, US (Residence), IN (Nationality), (Designated only for: US)
GUO Xiaojia, 713 Robert Frost Drive, Branford, CT 06405, US, US (Residence), CN (Nationality), (Designated only for: US)
PATTURAJAN Meera, 45 Harrison Avenue, Apartment 1C, Branford, CT 06405, US, US (Residence), IN (Nationality), (Designated only for: US)
TAUPIER Raymond J, 34 Pardee Place Extension, East Haven, CT 06512, US, US (Residence), US (Nationality), (Designated only for: US)
BURGESS Catherine E, 90 Carriage Hill Drive, Weathersfield, CT 06109, US, US (Residence), US (Nationality), (Designated only for: US)
ZERHUSEN Bryan D, 337 Monticello Drive, Branford, CT 06405, US, US (Residence), US (Nationality), (Designated only for: US)
KEKUDA Ramesh, 168 Lockwood Avenue, Stamford, CT 06902, US, US (Residence), IN (Nationality), (Designated only for: US)
SPYTEK Kimberly A, 28 Court Street, #1, New Haven, CT 06511, US, US (Residence), US (Nationality), (Designated only for: US)
GANGOLLI Esha A, 383 Walden Green, Branford, CT 06405, US, US (Residence), US (Nationality), (Designated only for: US)
FERNANDES Elma R, 77 Florence Road, #2B, Branford, CT 06405, US, US (Residence), IN (Nationality), (Designated only for: US)
GORMAN Linda, 141 Mill Street, Apartment 741, East Haven, CT 06512, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
ELRIFI Ivor R (agent), Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200233087 A2-A3 20020425 (WO 0233087)
Application: WO 2001US32496 20011017 (PCT/WO US0132496)
Priority Application: US 2000241040 20001017; US 2000241058 20001017; US 2000241063 20001017; US 2000241243 20001017; US 2000242152 20001020; US 2000242482 20001023; US 2000242611 20001023; US 2000242612 20001023; US 2000242880 20001024; US 2000242881 20001024; US 2000259028 20001229; US 2001269813 20010220; US 2001286324 20010425; US 2001294108 20010529; US 2001303698 20010709; US 2001981151 20011016
Parent Application/Grant:
Related by Continuation to: US 2000241040 20001017 (CIP); US 2000241058 20001017 (CIP); US 2000241063 20001017 (CIP); US 2000241243 20001017 (CIP); US 2000242152 20001020 (CIP); US 2000242482 20001023 (CIP); US 2000242611 20001023 (CIP); US 2000242612 20001023 (CIP); US 2000242880 20001024 (CIP); US 2000242881 20001024 (CIP); US 2000259028 20001229 (CIP); US 2001269813 20010220 (CIP); US 2001286324 20010425 (CIP); US 2001294108 20010529 (CIP); US 2001303968 20010709 (CIP); US 2001981151 20011016 (CIP)
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 112304

English Abstract
Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The

invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

French Abstract
L'invention concerne des sequences d'acide nucleique qui codent de nouveaux polypeptides. L'invention concerne egalement des polypeptides codes par ces sequences d'acide nucleique et des anticorps qui se lient de maniere immunospecifique au polypeptide, ainsi que des derives, des variants, des mutants, ou encore des fragments du polypeptide, du polynucleotide ou de l'anticorps susmentionnes. L'invention concerne encore des procedes de recherche, de diagnostic, de therapie afin de diagnostiquer, traiter et prevenir des troubles impliquant l'un(e) de ces nouveaux acides nucleiques humains et de ces nouvelles proteines humaines.

5/3,AB/69 (Item 11 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00900083
IMPROVED FORMULATIONS USING %HEAT% %SHOCK%/STRESS %PROTEIN% -PEPTIDE COMPLEXES
FORMULATIONS AMELIOREES UTILISANT DES COMPLEXES PEPTIDES-PROTEINES DE CHOC THERMIQUE/DE STRESS
Patent Applicant/Assignee:
UNIVERSITY OF CONNECTICUT HEALTH CENTER, 263 Farmington Avenue, Farmington, CT 06030, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
SRIVASTAVA Pramod K, 70 Pheasant Run, Avon, CT 06001, US, US (Residence), IN (Nationality), (Designated only for: US)
Legal Representative:
ANTLER Adriane M (et al) (agent), Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200232923 A2-A3 20020425 (WO 0232923)
Application: WO 2001US28840 20010917 (PCT/WO US0128840)
Priority Application: US 2000232779 20000915
Designated States: AU CA JP US
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
Publication Language: English
Filing Language: English
Fulltext Word Count: 43325

English Abstract
he present invention relates to methods for making compositions comprising heat shock proteins or alpha (2) macroglobulin ("alpha2M"), which compositions are immunogenic against a type of cancer or an agent of an infectious disease, and the compositions produced by the methods described herein. The invention further relates to methods for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. Specifically, the present invention provides a method of eliciting an immune response comprise administering to an individual a composition made by mixing an amount of a purified first complex comprising a first %heat% %shock% %protein% or alpha2M complexed to a peptide which displays antigenicity of an antigen of said type of cancer or antigenicity of an antigen of an agent of said infectious disease; and an equal or greater amount of a second %heat% %shock% %protein% or alpha2M that is not complexed in vitro to a peptide which displays antigenicity of an antigen of said type of cancer or antigenicity of an antigen of an agent of said infectious disease, respectively; and is not in the form of a complex, said complex having been isolated as a complex from cancerous tissue of said type of cancer or cells infected with said agent of infectious disease, respectively. Optionally, the methods further comprise administering antigen presenting cells sensitized with hsp-peptide or alpha2M-peptide complexes comprising peptides antigenic to cancer cells or to an agent of

an infectious disease.

French Abstract
La presente invention concerne des procedes pour produire des compositions contenant des proteines de choc thermique (hsp) ou de l'alpha-2-macroglobuline ("alpha2M"), lesquelles compositions provoquent une reponse immunologique contre un type de cancer ou un agent d'une maladie infectieuse, ainsi que les compositions produites selon lesdits procedes. Cette invention concerne egalement des procedes pour provoquer une reponse immunitaire ainsi que la prevention et le traitement de maladies infectieuses et de maladies neoplastiques metastatiques et primaires. La presente invention se rapporte en particulier a un procede pour provoquer une reponse immunitaire, consistant a administrer a un individu une composition produite en melangeant une quantite d'un premier complexe purifie, contenant une premiere proteine de choc thermique ou de l'alpha2M complexee, a un peptide affichant l'antigenicite d'un antigene dudit type de cancer ou l'antigenicite d'un antigene d'un agent de ladite maladie infectieuse, et en melangeant une quantite egale ou superieure d'une seconde proteine de choc thermique ou d'alpha2M non complexee in vitro a un peptide affichant l'antigenicite d'un antigene dudit type de cancer ou l'antigenicite d'un antigene d'un agent de ladite maladie infectieuse, respectivement. Cette composition ne se presente pas sous la forme d'unc omplexe, ledit complexe ayant ete isole en tant que complexe dut issu cancereux dudit type de cancer ou des cellules infectees par ledit agent de maladie infectieuse, respectivement. Ces procedes consistent eventuellement a administrer des cellules presentant l'antigene sensibilisees par des complexes hsp-peptides ou alpha2M-peptides contenant des peptides antigeniques aux cellules cancereuses ou a un agent d'une maladie infectieuse.

5/3,AB/70 (Item 12 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00894677
METHODS OF RECOVERING HEAT SHOCK PROTEINS AND COMPLEXES THEREOF
PROCEDES DESTINES A RECUPERER DES PROTEINES DE CHOC THERMIQUE ET DES COMPLEXES DE CES PROTEINES
Patent Applicant/Assignee:
UNIVERSITY OF CONNECTICUT HEALTH CENTER, 263 Farmington Avenue, Farmington, CT 06030, US, US (Residence), US (Nationality)
Inventor(s):
MENORET Antoine, 1 Oakland Terrace, Simsbury, CT 06070, US,
Legal Representative:
ANTLER Adriane M (et al) (agent), Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200228407 A1 20020411 (WO 0228407)
Application: WO 2000US26944 20000929 (PCT/WO US0026944)
Priority Application: WO 2000US26944 20000929
Designated States: CA JP
Publication Language: English
Filing Language: English
Fulltext Word Count: 13217
English Abstract
The present invention provides methods for efficient and concomitant recovery of multiple heat shock proteins (hsps) and/or %heat% %shock% %protein% complexes (hsp complexes) from a limited sample source. Disclosed are methods involving the use of heparin affinity chromatography which can separate hsps and/or hsp complexes including but not restricted to gp96, hsp86, hsp84, hsp70, hsp60 and hsp40 and hsp complexes thereof from a given sample. The invention also provides methods of recovering hsp complexes for the preparation of vaccines containing hsp complexes.

French Abstract
La presente invention concerne des procedes destines a recuperer de maniere efficace et concomitante plusieurs proteines de choc thermique

(hsp) et/ou plusieurs complexes de proteines de choc thermique (complexes hsp) a partir d'une source d'echantillon limitee. L'invention concerne notamment des procedes faisant intervenir la chromatographie d'affinite a l'heparine permettant de separer des proteines de choc thermique et/ou des complexes de proteines de choc thermique telles que par exemple gp96, hsp86, hsp84, hsp70, hsp60, et hsp40 et des complexes de ces proteines a partir d'un echantillon donne. L'invention concerne par ailleurs des procedes destines a recuperer des complexes de proteines de choc thermique pour la preparation de vaccins contenant des complexes de proteines de choc thermique.

5/3,AB/71 (Item 13 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00870887
METHOD OF IDENTIFYING CONFORMATION-SENSITIVE BINDING PEPTIDES AND USES THEREOF
PROCEDE D'IDENTIFICATION DE PEPTIDES DE LIAISON SENSIBLES A LA CONFORMATION ET UTILISATIONS CORRESPONDANTES
Patent Applicant/Assignee:
KARO BIO USA INC, 4222 Emperor Blvd. Suite 560, Durham, NC 27703-8466, US , US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
FOWLKES Dana M, 2013 Damascus Church Road, Chapel Hill, NC 27516, US, US (Residence), US (Nationality), (Designated only for: US)
BARNETT Thomas R, 101 Barnehill Place, Chapel Hill, NC 27514, US, US (Residence), US (Nationality), (Designated only for: US)
BUEHRER Benjamin, 5504 Garrett Road, Durham, NC 27707, US, US (Residence) , US (Nationality), (Designated only for: US)
Legal Representative:
BROWDY AND NEIMARK P L L C (et al) (agent), 624 Ninth Street N.W., Suite 300, Washington, DC 20001-5303, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200204956 A2-A3 20020117 (WO 0204956)
Application: WO 2001US21867 20010711 (PCT/WO US0121867)
Priority Application: US 2000614865 20000712; US 2001860688 20010521
Parent Application/Grant:
Related by Continuation to: US 2001860688 20010521 (CIP)
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 46490

English Abstract
Peptides which bind a cellular (surface or intracellular) receptor, such as a nuclear receptor, may be identified by screening a combinatorial peptide library presented in the form of cells each of which coexpress one member peptide and the receptor, together with a signal producing system for reporting binding. A "two-hybrid" assay is of particular interest. The screen may be carried out in the presence of a ligand, in particular, an exogenous ligand. If this screening is carried out for a plurality of different receptor conformations, then this library screening will also serve to identify conformation-specific peptides for the receptor, which may then be used in a panel for "fingerprinting"query compounds as to their ability to interact with the receptor in the presence of each of the panel peptides. These fingerprints may be compared to those of reference compounds with known biological activities mediated by that receptor.

French Abstract
L'invention concerne un procede d'identification de peptides qui se lient avec un recepteur cellulaire (en surface ou intracellulaire), du type recepteur nucleaire, par criblage de bibliotheque de peptides combinatoire se presentant sous la forme de cellules qui co-expriment chacune un peptide de la bibliotheque et le recepteur, avec utilisation de systeme de production de signaux notifiant la liaison. A cet egard, le dosage en "deux hybrides" presente un interet particulier. Le criblage peut etre realise en presence d'un ligand, en particulier un ligand exogene. S'il s'applique a une pluralite de conformations differentes de recepteurs, ce criblage de bibliotheque permet aussi d'identifier les peptides specifiques a telle ou telle conformation pour le recepteur considere, offrant ainsi la possibilite d'une utilisation dans un panel de peptides pour relever les "empreintes digitales" peptidiques de composes d'interet dont on cherche a determiner le potentiel d'interaction avec le recepteur en presence de chacun des peptides du panel. Il est possible de comparer les empreintes en question avec celles de composes de reference pour lesquels la mediation d'activites biologiques connues est assuree par le recepteur concerne.

5/3,AB/72 (Item 14 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00847101
JAVELINIZATION OF PROTEIN ANTIGENS TO HEAT SHOCK PROTEINS
COMPLEXATION D'ANTIGENES PROTEIQUES ET DE PROTEINES DE STRESS PAR SEQUENCE JAVELOT
Patent Applicant/Inventor:
ROTHMAN James E, 402 East 64th Street, Apt. 10B, New York, NY 10021, US, US (Residence), US (Nationality)
MAYHEW Mark, Apartment 27C, 150 York Avenue, New York, NY 10029, US, US (Residence), GB (Nationality)
HOE Mee, 10 South Cottenet Street, Apt. 2S, Irvington, NY 10533, US, US (Residence), MY (Nationality)
Legal Representative:
KOLE Lisa B (agent), Baker Botts LLP, 30 Rockefeller Plaza, New York, NY 10112, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200179259 A1 20011025 (WO 0179259)
Application: WO 2001US12567 20010417 (PCT/WO US0112567)
Priority Application: US 2000197462 20000417
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 8163

English Abstract
The present invention relates to antigenic complexes, wherein an antigenic complex comprises a peptide or protein containing a plurality of epitopes non-covalently joined to a %heat% %shock% %protein% via a molecular tether referred to as a "javelin". Such complexes do not require that each epitope Be defined, and may, in certain embodiments, elicit both antibody and cell-mediated immune reactions. The complexes of the invention may be used to induce therapeutic immune responses directed toward the treatment or prevention of infectious diseases and malignancies.

French Abstract
L'invention concerne des complexes antigeniques dans lesquels un peptide ou une proteine contenant de nombreux epitopes est lie, de maniere non

covalente, a une proteine de stress via une attache moleculaire appelee "javelot". De tels complexes ne requierent pas une definition de chaque epitope et peuvent, dans certaines realisations, provoquer des reactions immunes a la fois d'anticorps et a mediation cellulaire. Les complexes de l'invention peuvent etre utilises afin d'induire des reponses immunes therapeutiques en vue de traitement ou de prevention de maladies infectieuses et de malignites.

5/3,AB/73 (Item 15 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00820966
COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISORDERS
COMPOSITIONS ET TECHNIQUES POUR TRAITER DES TROUBLES NEURODEGENERATIFS
Patent Applicant/Assignee:
UNIVERSITY OF CONNECTICUT HEALTH CENTER, 263 Farmington Avenue, Farmington, CT 06030, US, US (Residence), US (Nationality)
Inventor(s):
SRIVASTAVA Pramod K, 70 Pheasant Run, Avon, CT 06001, US,
Legal Representative:
ANTLER Adriane M (et al) (agent), Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200152877 A1 20010726 (WO 0152877)
Application: WO 2001US1671 20010118 (PCT/WO US0101671)
Priority Application: US 2000489215 20000121
Designated States: AU CA JP
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
Publication Language: English
Filing Language: English
Fulltext Word Count: 19493
English Abstract
The present invention provides compositions comprising complexes of heat shock proteins non-covalently or covalently linked to antigens that display the antigenicity of antigens found in cells and tissues associated with the pathology of a neurodegenerative disease or disorder (such as Alzheimer's Disease). The compositions may be isolated from any tissue sources in which they exist, such as diseased human cells, non-human models for the disease orin vitro cultured cells that express neurodegenerative disorder-associated antigens. The invention further provides methods for the prevention and treatment of neurodegenerative diseases or disorders utilizing the compositions of the invention. The invention also provides kits comprising the compositions of the invention.

French Abstract
La presente invention concerne des compositions renferment des complexes de proteines de choc thermique liees de facon covalente ou non a des antigenes qui se caracterisent par l'antigenicite des antigenes presents dans les cellules et les tissus associes a la pathologie de troubles ou de maladies a caractere neurovegetatif (tels que la maladie d'Alzheimer). Ces compositions peuvent etre isolees a partir de tout tissu dans lesquelles elles sont presentes, tel que des cellules humaines malades, des modeles non humains pour la maladie ou des cellules cultivees in vitro qui expriment des antigenes associes a des troubles neurodegeneratifs. De plus, l'invention concerne des methodes de prevention et de traitement de maladies et de troubles d'ordre neurovegetatif reposant sur l'emploi des compositions selon l'invention. L'invention concerne egalement des kits renfermant lesdites compositions.

5/3,AB/74 (Item 16 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00806944
ANTIGEN-BINDING FRAGMENTS SPECIFIC FOR TUMOR ASSOCIATED ANTIGENS

FRAGMENTS DE LIAISON A L'ANTIGENE SPECIFIQUES AUX ANTIGENES ASSOCIES AUX TUMEURS

Patent Applicant/Assignee:
NOVOPHARM BIOTECH INC, 30 Novopharm Court, Toronto, Ontario M1B 2K9, CA, CA (Residence), CA (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
DAN Michael, 63 Gordon Road, North York, Ontario M2P 1E3, CA, CA (Residence), CA (Nationality), (Designated only for: US)
ENTWISTLE Joycelyn, 380 Lindenwood Drive E., Winnipeg, Manitoba R3P 2H1, CA, CA (Residence), CA (Nationality), (Designated only for: US)
FAST Darren, 49 Nutley Circle, Winnipeg, Manitoba R2N 1S2, CA, CA (Residence), CA (Nationality), (Designated only for: US)
KAPLAN Howard, 18 Hillhouse Road, Winnipeg, Manitoba R2V 2V9, CA, CA (Residence), CA (Nationality), (Designated only for: US)
LEWIS Keith, Box 36, R.R. #2, Ste. Anne, Manitoba R5H 1R2, CA, CA (Residence), CA (Nationality), (Designated only for: US)
MACDONALD Glen, 475 Raglan Road, Winnipeg, Manitoba R3G 3E4, CA, CA (Residence), CA (Nationality), (Designated only for: US)
MAITI Pradip, 38 Swan Lake Bay, Winnipeg, Manitoba R3T 4W1, CA, CA (Residence), CA (Nationality), (Designated only for: US)
Legal Representative:
HELLER David (agent), Ridout & Maybee, Suite 2400, One Queen Street East, Toronto, Ontario M5C 3B1, CA,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200140292 A1 20010607 (WO 0140292)
Application: WO 99CA1141 19991129 (PCT/WO CA9901141)
Priority Application: WO 99CA1141 19991129
Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 51881

English Abstract
The present invention relates to antigen-binding fragments that are specific for stressprotein-peptide complexes specifically associated with tumors, particularly human tumors, and compositions thereof. The compositions are suitable for diagnostic and pharmaceutical use. The invention further provides methods of making and screening for the antigen-binding fragments. The invention further encompasses compositions containing cancer-associated stress protein-peptide complexes (including derivatives thereof) and methods of use thereof. The cancer-specific stress protein-peptide complexes ("SPPC"s) are particularly useful in eliciting cancer-specific immunogenic responses against a plurality of cancers. The invention also provides novel phage display libraries for use in producing further SPPCs and anti-SPPCs of the invention.

French Abstract
L'invention concerne des fragments de liaison a l'antigene qui sont specifiques aux complexes proteino-peptidiques sous tension plus particulierement associes aux tumeurs, aux tumeurs chez l'Homme en particulier, ainsi que les compositions de ces fragments. Les compositions sont adaptees a une utilisation pharmaceutique ou au diagnostic. L'invention concerne egalement les procedes de fabrication et de depistage des fragments de liaison a l'antigene. L'invention comprend aussi les compositions contenant des complexes proteino-peptidiques sous tension associes au cancer (y compris les derives de ces complexes) ainsi que leurs procedes d'utilisation. Les complexes proteino-peptidiques sous tension associes au cancer sont particulierement utiles au declenchement de reponses immunogenes specifiques au cancer pour lutter contre de nombreux cancers. L'invention concerne egalement des banques d'affichage des nouveaux phages qui sont utilisees pour la production de nouveaux

complexes proteino-peptidiques sous tension et de nouveaux anti complexes proteino-peptidiques sous tension decrits dans l'invention.

5/3,AB/75 (Item 17 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00800975
METHODS AND COMPOSITIONS FOR PROTECTION AGAINST BOVINE HERPESVIRUS 1
METHODES ET COMPOSITIONS DE PROTECTION CONTRE L'HERPESVIRUS BOVIN 1
Patent Applicant/Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, 3835 Holdrege Street, Lincoln, NE 68588-0745, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
SRIKUMARAN Subramaniam, The Board of Regents of the University of Nebraska, 3835 Holdrege Street, Lincoln, NE 68588-0745, US, US (Residence), US (Nationality), (Designated only for: US)
NAVARATNAM Manjula, The Board of Regents of the University of Nebraska, 3835 Holdrege Street, Lincoln, NE 68588-0745, US, US (Residence), LK (Nationality), (Designated only for: US)
Legal Representative:
BUTLER James E (et al) (agent), Senniger, Powers, Leavitt & Roedel, One Metropolitan Square, 16th floor, St. Louis, MO 63102, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200134184 A2-A3 20010517 (WO 0134184)
Application: WO 2000US30359 20001103 (PCT/WO US0030359)
Priority Application: US 99163725 19991105
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 11303

English Abstract
The present invention relates to methods and compositions for eliciting an immune response against bovine herpesvirus 1 epitopes. The methods comprise combining at least one %heat% %shock% %protein% with at least one bovine herpesvirus 1 epitope to form a purified epitope/%heat% %shock% %protein% %complex% and administration of an immune system stimulating amount of the purified epitope/%heat% %shock% %protein% %complex%. The compositions comprise, a purified epitope/%heat% %shock% %protein% %complex% comprising at least one bovine herpesvirus 1 epitope complexed with at least one %heat% %shock% %protein%, and a pharmaceutically acceptable carrier, diluent or excipient.

French Abstract
La presente invention concerne des methodes et des compositions permettant de provoquer une reponse immune contre des epitopes de l'herpesvirus bovin 1. Ces methodes consistent a realiser une combinaison d'au moins une proteine de choc thermique avec au moins un epitope de l'herpesvirus bovin 1, afin de former un complexe d'epitope/proteine de choc thermique purifie, ainsi qu'a administrer une dose stimulant le systeme immun du complexe d'epitope/proteine de choc thermique purifie. Les compositions contiennent un complexe d'epitope/proteine de choc thermique purifie comprenant au moins un epitope d'herpes-virus bovin 1 complexe avec au moins une proteine de choc thermique ainsi qu'un support, un diluent et un excipient acceptables sur le plan pharmaceutique.

5/3,AB/76 (Item 18 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT
(c) 2004 WIPO/Univentio. All rts. reserv.

00565659
METHODS FOR USING HEAT SHOCK PROTEINS BOUND TO DNA OR RNA
UTILISATION DE PROTEINES DU STRESS LIEES A L'ADN OU A L'ARN
Patent Applicant/Assignee:
  THE UNIVERSITY OF NEW MEXICO,
Inventor(s):
  MOSELEY Pope L,
  WALLEN Erik S,
  CURRY Russell A,
Patent and Priority Information (Country, Number, Date):
  Patent: WO 200029032 A1 20000525 (WO 0029032)
  Application: WO 99US26869 19991112 (PCT/WO US9926869)
  Priority Application: US 98108176 19981113
Designated States: AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL
  PT SE
Publication Language: English
Fulltext Word Count: 4504

English Abstract
  A method for transfecting an oligonucleotide into a cell comprising:
  providing a purified %heat% %shock% %protein%-oligonucleotide %complex%
  comprising a %heat% %shock% %protein% component and an oligonucleotide
  component; and administering the %heat% %shock% %protein%-oligonucleotide
  %complex% to an individual to transfect at least a portion of the
  oligonucleotide component into a cell including at least one HSP
  receptor.

French Abstract
   Cette invention porte sur la transfection d'un oligonucleotide dans une
  cellule. A cet effet, on commence par realiser un complexe purifie
  proteine du stress et oligonucleotide reunissant un composant proteine du
  stress et un composant oligonucleotide. On administre ensuite ce complexe
  proteine du stress et oligonucleotide a un individu de facon a
  transfecter au moins une partie de l'oligonucleotide dans une cellule
  comprenant au moins un recepteur de proteine du stress.

 5/3,AB/77   (Item 19 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2004 WIPO/Univentio. All rts. reserv.

00556455
METHODS FOR GENERATING ANTIGEN-REACTIVE T CELLS i(IN VITRO)
PROCEDE D'OBTENTION I(IN VITRO) DE CELLULES T REAGISSANT AUX ANTIGENES
Patent Applicant/Assignee:
  UNIVERSITY OF CONNECTICUT HEALTH CENTER,
Inventor(s):
  SRIVASTAVA Pramod K,
Patent and Priority Information (Country, Number, Date):
  Patent: WO 200019828 A1 20000413 (WO 0019828)
  Application: WO 99US22856 19991004 (PCT/WO US9922856)
  Priority Application: US 98166401 19981005
Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
  ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT
  LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
  UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD
  RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF
  CG CI CM GA GN GW ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 20455

English Abstract
  The present invention provides methods for generating antigen-reactive T
  cells i(in vitro) comprising priming immune cells and incubating the
  primed immune cells i(in vitro) with a non-covalent complex of an %heat%
  %shock% %protein% and an antigenic molecule. The present invention

further relates to methods for generating antigen-reactive CD4+ T cells for immunotherapy. Methods and compositions are also disclosed for the treatment and prevention of cancer or infectious disease in a subject comprising administering to the subject MHC matched antigen-reactive T cells that are generated i(in vitro) by the present methods.

French Abstract

L'invention porte sur des procedes d'obtention i(in vitro) de cellules T reagissant aux antigenes consistant a amorcer des cellules immunes puis a les incuber i(in vitro) avec un complexe non covalent d'une proteine de choc thermique et d'une molecule d'antigene. L'invention porte egalement sur des procedes d'obtention de cellules CD4+ T reagissant aux antigenes a des fins d'immunotherapie, et sur des procedes et compositions utilisees pour le traitement et la prevention du cancer ou de maladies infectieuses chez un sujet, consistant a lui administrer des cellules T reagissant aux antigenes, pendant du CMH, obtenues i(in vitro) par les procedes ci-dessus.

5/3,AB/78 (Item 20 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00533273
METHODS AND KITS FOR DISCOVERY OF RNA-BINDING COMPOUNDS
PROCEDES ET KITS D'IDENTIFICATION DE COMPOSES DE FIXATION D'ARN
Patent Applicant/Assignee:
RIBOTARGETS LIMITED,
Inventor(s):
KARN Jonathan,
PRESCOTT Catherine Denise,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9964625 A2 19991216
Application: WO 99GB1761 19990604 (PCT/WO GB9901761)
Priority Application: GB 9812196 19980605; GB 994790 19990302
Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 26471
English Abstract

A solution-based assay for identifying RNA binding compounds, based on competition. The assay comprises a reporter molecule carrying a fluorescent or chromogenic group that can form a one-to-one complex with an RNA target molecule carrying a second fluorescent or chromogenic group in such a way that the two groups are in sufficient proximity for fluorescence resonance energy transfer and/or quenching to take place. Addition of a compound-to-be-tested prevents formation of the complex and thereby increases the fluorescence of the RNA target and/or reporter molecules relative to the signal obtained in the absence of the test compound. Quantitative screening methods are also included.

French Abstract

La presente invention concerne un dosage utilisant une solution permettant d'identifier des composes de fixation d'ARN, mis en competition. Ce dosage renferme une molecule porteuse transportant un groupe fluorescent ou chromogene pouvant former un complexe a correspondance un pour un avec une molecule cible d'ARN transportant un second groupe fluorescent ou chromogene, de maniere a ce que ces deux groupes soient suffisamment proches l'un de l'autre pour permettre le transfert et/ou l'extinction d'energie de resonance par fluorescence. L'addition d'un compose devant etre teste empeche la formation du complexe, augmentant ainsi la fluorescence des molecules cibles et/ou porteuses d'ARN, en fonction du signal obtenu en l'absence du compose d'analyse. Par ailleurs, cette invention concerne des procedes de selection quantitative.

5/3,AB/79 (Item 21 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00523376
METHOD OF PREDICTING THE ABILITY OF COMPOUNDS TO MODULATE THE BIOLOGICAL ACTIVITY OF RECEPTORS
METHODE PERMETTANT DE PREVOIR LA CAPACITE DE COMPOSES DE MODULER L'ACTIVITE BIOLOGIQUE DE RECEPTEURS
Patent Applicant/Assignee:
NOVALON PHARMACEUTICAL CORPORATION,
PAIGE Lisa A,
HAMILTON Paul T,
FOWLKES Dana M,
BUEHRER Benjamin,
BARNETT Tom,
MCDONNELL Donald P,
CHRISTENSEN Dale J,
Inventor(s):
PAIGE Lisa A,
HAMILTON Paul T,
FOWLKES Dana M,
BUEHRER Benjamin,
BARNETT Tom,
MCDONNELL Donald P,
CHRISTENSEN Dale J,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9954728 A2 19991028
Application: WO 99US6664 19990326 (PCT/WO US9906664)
Priority Application: US 9882756 19980423; US 9899656 19980909; US 99115345 19990108
Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 48130

English Abstract
The ability of a query compound to modulate the biological activity of a receptor in a multicellular organism is predicted on the basis of its interaction with that receptor in the presence of various member of a panel of BioKeys. The BioKeys are ligands, especially peptides or nucleic acids, known to modify the conformation of the receptor. This interaction data, known as a "fingerprint", is compared to the fingerprints for reference compounds with known biological activities mediated by that receptor. In the "molecular braille" (MB) embodiment of the present invention, the reference and test fingerprints are based on i(in vitro) (cell-free) assays. In the "cellular-braille" (CB) embodiment of the present invention, the reference and test fingerprints are based on cellular assays (but not on assays of whole multicellular organisms, or their organs or tissues).

French Abstract
La presente invention permet de prevoir l'aptitude d'un compose d'interet a moduler l'activite biologique d'un recepteur dans un organisme multicellulaire a partir de son interaction avec ledit recepteur en presence de divers membres d'un groupe de bio-cles. Les bio-cles sont des ligands, en particulier des peptides ou des acides nucleiques, connus pour modifier la conformation du recepteur. Ces donnees d'interaction constituent ce que l'on appelle une "empreinte digitale", qui est comparee aux empreintes de composes de reference aux activites biologiques connues et dont le recepteur assure la mediation. Dans la realisation dite "en braille moleculaire" de la presente invention, les empreintes digitales de reference et de test sont basees

sur des essais i(in vitro) (acellulaires). Dans la realisation dite "en braille cellulaire" de la presente invention, les empreintes digitales de reference et de test sont basees sur des essais cellulaires (mais non pas sur des essais d'organismes multicellulaires complets, ou de leurs organes ou tissus).

5/3,AB/80 (Item 22 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00517562
METHODS FOR USING HEAT SHOCK PROTEINS
METHODES D'UTILISATION DES PROTEINES DE CHOC THERMIQUE
Patent Applicant/Assignee:
THE UNIVERSITY OF NEW MEXICO,
Inventor(s):
WALLEN Erik,
MOSLEY Pope,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9948914 A1 19990930
Application: WO 99US6432 19990325 (PCT/WO US9906432)
Priority Application: US 9879426 19980326
Designated States: BR CA JP MX AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 3527

English Abstract
The present invention provides a %heat% %shock% %protein% immunotoxin comprising: at least a fragment of a %heat% %shock% %protein%, the fragment being capable of being bound by an immune cell; and a toxin bound to the fragment. The present invention also provides a method for decreasing the number of immune cells in an individual using the %heat% %shock% %protein% immunotoxins of the present invention. In addition, the present invention provides a method for decreasing the number of immune cells in an organ using the %heat% %shock% %protein% immunotoxins of the present invention.

French Abstract
La presente invention concerne une immunotoxine de proteines de choc thermique comprenant : au moins un fragment de proteine de choc thermique, ledit fragment pouvant etre lie par une cellule immunitaire ; et une toxine liee au fragment. La presente invention concerne egalement une methode, qui utilise les immunotoxines des proteines de choc thermique de l'invention, et qui permet de reduire le nombre de cellules immunitaires chez un individu . En outre, la presente invention concerne une methode, qui utilise les immunotoxines des proteines de choc thermique de l'invention, et qui permet de reduire le nombre de cellules immunitaires dans un organe.

5/3,AB/81 (Item 23 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00497830
METHOD FOR PURIFYING HEAT SHOCK PEPTIDES COMPLEXES
PROCEDE SERVANT A PURIFIER DES COMPLEXES DE PEPTIDES ET DE PROTEINES DU STRESS
Patent Applicant/Assignee:
THE UNIVERSITY OF NEW MEXICO,
Inventor(s):
WALLEN Erik S,
MOSELEY Pope L,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9929182 A1 19990617
Application: WO 98US25734 19981204 (PCT/WO US9825734)
Priority Application: US 97985548 19971205; US 97986234 19971205

Designated States: BR CA JP MX AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 5670

English Abstract
The present invention provides a method for synthesizing %heat% %shock% %protein%-peptide complexes comprising the steps of: adding a shock protein to a denatured protein matrix to bind the %heat% %shock% %protein% to the denatured protein matrix; and adding a complexing solution comprising a peptide to elute a %heat% %shock% %protein%-peptide %complex%. The present invention also provides a %heat% %shock% %protein% -peptide %complex% synthesized by the method of the invention. In addition the present invention provides an apparatus for synthesizing %heat% %shock% %protein%-peptide complexes comprising a %heat% %shock% %protein% %complex% bound to a denatured protein matrix. The present invention also provides a method for treating an allergic disease in which a %heat% %shock% %protein%-antigen %complex% is administered to a mammal in an amount sufficient to reduce the susceptibility of the mammal to a Th2 response for the allergic disease. The method of the present invention can be used either to prevent an invididual from having an allergic reaction to an allergic disease or to reduce the effects of an allergic disease in an individual already suffering from the allergic disease.

French Abstract
L'invention concerne un procede servant a realiser la synthese de complexes constitues par des peptides et par des proteines du stress et consistant a effectuer l'apport d'une proteine du stress a une matrice de proteine denaturee afin de lier la proteine du stress a la matrice de proteine denaturee et a ajouter une solution chelatante contenant un peptide afin d'eluer un complexe constitue par la proteine du stress et le peptide. Elle concerne egalement un complexe constitue par une proteine du stress et par un peptide dont la synthese a ete effectuee au moyen de ce procede. Elle concerne, de plus, un dispositif servant a effectuer la synthese de complexes composes d'une proteine du stress liee a une matrice de proteine denaturee. Elle concerne egalement un procede servant a traiter une maladie allergique et consistant a administrer un complexe constitue par une proteine du stress et un antigene a un mammifere en quantite suffisante pour diminuer la susceptibilite de ce mammifere a une reaction Th2 pour la maladie allergique. On peut mettre en application ce procede soit pour empecher la reaction allergique d'un individu a une maladie allergique, soit pour limiter les effets d'une maladie allergique chez un individu deja atteint de cette maladie allergique.

5/3,AB/82 (Item 24 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00425153
METHODS FOR GENERATING CYTOTOXIC T CELLS IN VITRO
PROCEDES DE GENERATION IN VITRO DE LYMPHOCYTES T CYTOTOXIQUES
Patent Applicant/Assignee:
FORDHAM UNIVERSITY,
Inventor(s):
SRIVASTAVA Pramod K,
BINDER Robert,
BLACHERE Nathalie E,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9815616 A1 19980416
Application: WO 97US18110 19971006 (PCT/WO US9718110)
Priority Application: US 96726967 19961007
Designated States: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU ID IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA UZ VN YU GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English
Fulltext Word Count: 15054
English Abstract
The present invention provides methods for generating antigen-reative cytotoxic T cells in vitro comprising culturing immune cells and antigenic cells that have at least one MHC allele in common (and preferably, are syngeneic), in which the antigenic cells have been treated according to the methods of the invention. The antigenic cells are treated by subjecting them to osmotic shock followed by irradiation. As a result, a subset of T cells are activated and mature into antigen-reactive cytotoxic T cells. The effectiveness of the procedure may be enhanced by repeated restimulations and/or the addition of %heat% %shock% %protein%-peptide complexes. Methods and compositions are also disclosed for the treatment and prevention in a subject of cancer or infectious disease comprising administering to the subject matched cytotoxic T cells that are generated in vitro by the present methods.

French Abstract
L'invention concerne des procedes servant a generer in vitro des lymphocytes T cytotoxiques presentant une reactivite aux antigenes, ce qui consiste a effectuer la culture de cellules immunes et de cellules antigeniques possedant au moins en commun un allele de MHC (et etant, de preference, syngeniques), les cellules antigeniques ayant ete traitees selon ces procedes. On traite les cellules antigeniques en les soumettant a un choc osmotique suivi par une irradiation. De ce fait, un sous-ensemble de lymphocytes T est active et arrive a maturite en tant que lymphocytes T cytotoxiques presentant une reactivite aux antigenes. On peut ameliorer l'efficacite du procede, soit au moyen de restimulations repetees, soit par apport de complexes de choc thermique constitues par des proteines et par des peptides. L'invention concerne egalement des procedes et des compositions servant au traitement et a la prevention du cancer ou de maladies infectieuses, ce qui consiste a administrer a l'individu atteint de l'une ou de l'autre de ces maladies des lymphocytes T cytotoxiques apparies, generes in vitro au moyen de ces procedes.

5/3,AB/83 (Item 25 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00366494
%HEAT% %SHOCK% %PROTEIN%-BASED VACCINES AND IMMUNOTHERAPIES
VACCINS ET IMMUNOTHERAPIES A BASE DE PROTEINES DU STRESS
Patent Applicant/Assignee:
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH,
ROTHMAN James E,
HARTL F Ulrich,
HOE Mee H,
HOUGHTON Alan,
TAKEUCHI Yoshizumi,
MAYHEW Mark,
Inventor(s):
ROTHMAN James E,
HARTL F Ulrich,
HOE Mee H,
HOUGHTON Alan,
TAKEUCHI Yoshizumi,
MAYHEW Mark,
Patent and Priority Information (Country, Number, Date):
Patent: WO 9706821 A1 19970227
Application: WO 96US13363 19960816 (PCT/WO US9613363)
Priority Application: US 952490 19950818; US 952479 19950818
Designated States: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English

Fulltext Word Count: 12615

English Abstract
The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one %heat% %shock% %protein% in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.

French Abstract
L'invention concerne des methodes et des compositions permettant d'induire une reponse immunitaire chez un sujet. On administre a ce dernier une quantite efficace d'une ou plusieurs proteines du stress associees a un ou plusieurs antigenes cibles definis. Ces methodes et compositions peuvent etre utilisees dans le traitement des maladies infectieuses et des cancers.

5/3,AB/84 (Item 1 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent

Dialog Acc No: 10243452 IFI Acc No: 2002-0187159 IFI Acc No: 2002-0048217
Document Type: C
THE USE OF %HEAT% %SHOCK% %PROTEIN% 70 PREPARATIONS IN VACCINATION AGAINST CANCER AND INFECTIOUS DISEASE; COMPLEX IS OBTAINED FROM TUMOR CELLS OR CELLS INFECTED WITH A VIRUS, %BACTERIA% OR OTHER INFECTIOUS AGENT.
Inventors: Srivastava Pramod K (US)
Assignee: Mount Sinai School of Medicine of City Univ of New York; Mount Sinai School of Medicine of New York Univ
Assignee Code: 57466
Publication (No,Date), Applic (No,Date):
US 20020187159 20021212 US 2002180562 20020625
Publication Kind: A1
Continuation Pub(No),Applic(No,Date): US 5997873 US 94180685 19940113
Division Pub(No),Applic(No,Date): PENDING US 99454734 19991206
Priority Applic(No,Date): US 2002180562 20020625; US 94180685 19940113; US 99454734 19991206

Abstract: The use of cognate %heat% %shock% %protein% 70-peptide complex to elicit an immune response against cancer and viral, %bacterial% and other infectious agents.

5/3,AB/85 (Item 2 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent

Dialog Acc No: 10238513 IFI Acc No: 2002-0182220 IFI Acc No: 2002-0046825
Document Type: C
USE OF %HEAT% %SHOCK% %PROTEIN% 70 PREPARATIONS IN VACCINATION AGAINST CANCER AND INFECTIOUS DISEASE; ISOLATING A %HEAT% %SHOCK% %PROTEIN% 70-PEPTIDE COMPLEX FROM THE MAMMAL FROM TUMOR CELLS OR CELLS INFECTED WITH A VIRUS, %BACTERIA% OR INFECTIOUS AGENT; AND ADMINISTERING THE %HEAT% %SHOCK% %PROTEIN% PEPTIDE %COMPLEX%
Inventors: Srivastava Pramod K (US)
Assignee: Mount Sinai School of Medicine of City Univ of New York; Mount Sinai School of Medicine of New York Univ
Assignee Code: 57466
Publication (No,Date), Applic (No,Date):
US 20020182220 20021205 US 2002180592 20020625
Publication Kind: A1
Continuation Pub(No),Applic(No,Date): US 5997873 US 94180685 19940113
Division Pub(No),Applic(No,Date): PENDING US 99454734 19991206
Priority Applic(No,Date): US 2002180592 20020625; US 94180685 19940113;

US 99454734 19991206
Abstract: The use of cognate %heat% %shock% %protein% 70-peptide complex to elicit an immune response against cancer and viral, %bacterial% and other infectious agents.

5/3,AB/86 (Item 3 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent

Dialog Acc No: 3211403 IFI Acc No: 9932292
Document Type: C
STRESS PROTEIN-PEPTIDE COMPLEXES AS PROPHYLACTIC AND THERAPEUTIC VACCINES AGAINST INTRACELLULAR PATHOGENS; COMPLEX OF A MAMMALIAN STRESS PROTEIN NONCOVALENTLY ASSOCIATED WITH A PEPTIDE THAT IS PRESENT IN A EUKARYOTIC CELL INFECTED WITH SAID PATHOGEN BUT NOT PRESENT IN SAID CELL WHEN SAID CELL IS NOT INFECTED WITH SAID PATHOGEN
Inventors: Srivastava Pramod K (US)
Assignee: Mount Sinai School of Medicine of City Univ of New York
Assignee Code: 57466 Document Type: REASSIGNED
Publication (No,Date), Applic (No,Date):
US 5961979 19991005 US 94210421 19940316
Publication Kind: A
Calculated Expiration: 20161005
(Cited in 005 later patents)
Priority Applic(No,Date): US 94210421 19940316

Abstract: Disclosed is a family of vaccines that contain stress proteinpeptide complexes which when administered to a mammal are operative at initiating in the mammal cytotoxic T cell responses against preselected intracellular pathogens. Also disclosed are methodologies for preparing and administering vaccines containing stress protein-peptide complexes.

5/3,AB/87 (Item 1 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)

07535336 Supplier Number: 63170740
EUROPEAN PATENT DISCLOSURES.(Brief Article)
BIOWORLD Today, vVol. 11, nNo. 129, pNA
July 6, 2000
Language: English Record Type: Fulltext
Article Type: Brief Article
Document Type: Magazine/Journal; Trade
Word Count: 2553

5/3,AB/88 (Item 1 from file: 9)
DIALOG(R)File 9:Business & Industry(R)

4115312 Supplier Number: 105618560
Phase III. (from pipeline to market).

R&D Directions, v 9, n 6, p 51
June 2003
DOCUMENT TYPE: Journal ISSN: 1079-9397 (United States)
LANGUAGE: English RECORD TYPE: Fulltext
WORD COUNT: 5588

TEXT:
9-VALENT PNEUMOCOCCAL and MENINGOCOCCAL GROUP C CONJUGATE VACCINE For the prevention of meningococcal group C meningitis and pneumococcal infection.

Wyeth

ABI-007 (paclitaxel) For the treatment of metastatic breast cancer.

American Pharmaceutical Partners

ABT-773 For the treatment of Haemophilus influenzae and resistant pneumococcal infections.
Abbott Laboratories

ACITREL (omeprazole) For the prevention of upper gastrointestinal bleeding in critically ill adult patients.

Tap Pharmaceutical Products

5/3,AB/89 (Item 2 from file: 9)
DIALOG(R)File 9:Business & Industry(R)

4086992 Supplier Number: 106026324
From pipeline to market: phase I. (M-Z).

Med Ad News, v 22, n 7, p S101
July 2003
DOCUMENT TYPE: Journal ISSN: 0745-0907 (United States)
LANGUAGE: English RECORD TYPE: Fulltext
WORD COUNT: 3080

TEXT:
M40403 (superoxide dismutase) For the treatment of cancer.

MALARIA VACCINE For the treatment of malaria.

MetaPhore Pharmaceuticals

Vical

MALARIVAX For the treatment of malaria.

Apovia
MARSTEM For the treatment of pancytopenia following chemotherapy in breast cancer patients and for the prevention of pancytopenia following chemotherapy in breast cancer patients.

Maret Pharmaceuticals

MAX-AD FACTOR VIII For the treatment of hemophilia A.

Baxter Healthcare

MAXDERM For the treatment of oral mucositis and for the treatment of radiation-induced dermatitis.

5/3,AB/90 (Item 3 from file: 9)
DIALOG(R)File 9:Business & Industry(R)

4086990 Supplier Number: 106026322
From pipeline to market: phase II. (M-Z).

Med Ad News, v 22, n 7, p S78
July 2003
DOCUMENT TYPE: Journal ISSN: 0745-0907 (United States)
LANGUAGE: English RECORD TYPE: Fulltext
WORD COUNT: 4641

TEXT:
MAB 2C4 For the treatment of solid tumors.

Roche

MAC-321 For the treatment of metastatic breast cancer and the treatment of nonsmall cell lung cancer.

Wyeth

MACUGEN (pegaptanib) For the treatment of diabetic macular edema.
EyeTech Pharmaceuticals and Pfizer

MAGNEVIST (gadopentetate) For use as a cardiac myocardial perfusion imaging.

Berlex Laboratories

MALARIA VACCINE For the prevention of malaria.

GlaxoSmithKline

MALE FERTILITY CONTROL (gestagen and androgen) For male contraception.

5/3,AB/91 (Item 4 from file: 9)
DIALOG(R)File 9:Business & Industry(R)

4086988 Supplier Number: 106026320
From pipeline to market: phase III. (A-Z).

Med Ad News, v 22, n 7, p S51
July 2003
DOCUMENT TYPE: Journal ISSN: 0745-0907 (United States)
LANGUAGE: English RECORD TYPE: Fulltext
WORD COUNT: 5585

TEXT:
9-VALENT PNEUMOCOCCAL and MENINGOCOCCAL GROUP C CONJUGATE VACCINE For the prevention of meningococcal group C meningitis and pneumococcal infection.

Wyeth

ABI-007 (paclitaxel) For the treatment of metastatic breast cancer.

American Pharmaceutical Partners

ABT-773 For the treatment of Haemophilus influenzae and resistant pneumococcal infections.
Abbott Laboratories

ACITREL (omeprazole) For the prevention of upper gastrointestinal bleeding in critically ill adult patients.

Tap Pharmaceutical Products

?